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9General introduction
The incidence of skin cancer is increasing in the Netherlands the past decades [1, 2]. Basal 
cell carcinoma (BCC) is the most common skin cancer, followed by squamous cell carcinoma 
(SCC) and melanoma. The term non-melanoma skin cancer (NMSC) is often incorrectly 
used for BCC and SCC together. NMSC also could include other types of skin cancer such as 
Merkel cell carcinoma, atypical fibroxanthoma and cutaneous T cell lymphoma. Therefore 
we prefer to use keratinocyte carcinoma (KC).
More than 49,000 patients were newly diagnosed with skin cancer in the Netherlands in 
2015 [3]. This included 5,978 new patients with melanoma, ~ 34,000 patients with BCC 
and 8,902 newly diagnosed SCC patients. This large amount of new patients does not 
even reflect the total number of skin cancers, as the Netherlands Cancer Registry only 
registered the first BCC and/or SCC per patient up to mid-2016, while many KC patients will 
develop subsequent skin cancers [4].
The mortality of KC is generally low and treatment is usually surgical or topical [5]. It 
usually does not involve lengthy systemic treatments with associated (severe) side effects.
Patient reported outcomes and quality of life
Patient reported outcomes (PROs) are outcomes about a disease, health or treatment 
directly from patients without interpretation. It includes quality of life (QoL), but also 
other outcomes such as treatment satisfaction, functional status and well-being and it 
reflects how patients feel [6].
QoL is defined by the World Health Organization (WHO) as ‘an individual’s perception of 
their position in life in the context of the culture and value system in which they live and in 
relation to their goals, expectations, standards and concerns. This broad ranging concept 
is in a complex way affected by the person’s physical health, psychological state, level 
of independence, social relationships, personal beliefs and their relationship to salient 
features of their environment’. Health-related quality of life (HRQoL) concerns only the 
health aspects of QoL, but this is considered as a fluid construct. Because if the disease is 
severe enough, it will impact the whole QoL domain.
Health-related quality of life in dermatologic oncology
Over the past decades PRO and HRQoL more specifically, became increasingly important 
in dermatology patients . The focus of HRQoL assessments at first was on common chronic 
non-life-threatening diseases such as psoriasis and atopic dermatitis and it has proven to 
be an essential outcome for studies and in daily practice [7]. Subsequently, the measure-
ment of PROs has spread to other chronic less common skin diseases as well. However, 
PRO in cutaneous malignant tumours were not widely studied which may be due to fact 
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that having a skin cancer was considered a discrete event instead of possibly being part 
of a chronic disease (with multiple tumours). Also preliminary studies yielded little to no 
impairment on generic or dermatology specific instruments [8-21].
When you also take the rapidly increasing incidence in skin cancers in account, implemen-
tation of PRO and HRQoL in diagnosis and treatment is necessary, especially in KC with the 
high incidence [2, 22, 23].
With the introduction of the concept of skin cancer as a chronic disease, new non-invasive 
treatments for cutaneous (pre)malignancies and the development of skin cancer specific 
tools, the lack of knowledge on PRO in this context should be re-explored.
In the past, most attention in PRO and HRQoL research in dermatologic oncology has focused 
on malignant melanoma (MM) patients, because of the associated mortality and the impact 
of systemic therapies. It was found that the HRQoL impact in these patients is comparable 
to that of others cancers and that assessment is pivotal for further disease management 
[24]. KCs however are rarely life-threatening, but may be associated with HRQoL impair-
ment. Because of low mortality, many KC patients are likely to develop multiple carcinomas 
and actinic keratoses (AK) during their lives. Having multiple carcinomas has been regarded 
as discrete events in the past, but is increasingly being recognized as a chronic illness [25]. 
The condition “actinic neoplasia syndrome (ANS)”, as proposed by Weinstock et al., is pos-
sibly the best way to consider this emerging group of patients and one of the main reasons 
to investigate the impact of this chronic condition on the HRQoL [20].
As in all other chronic diseases in dermatology, assessment of the HRQoL is pivotal for 
optimizing disease management, supportive care and integrating patient preferences. 
Evaluation of the impact on PRO is a way in which new treatments can discriminate them-
selves from conventional treatments including surgery. If treatments are equally (or even 
less) effective, PROs may shift the balance in favour of innovative therapies.
First study on HRQoL impact of KC
One of the first published studies addressing the impact of BCC on HRQoL demonstrated 
little impact with only minimal differences before and after treatment [26]. Measurements 
were performed using the UK Sickness Impact profile (UKSIP), a measure of general health 
status, and the Dermatology Life Quality Index (DLQI), a dermatology specific question-
naire. In this study the authors noticed very low overall scores (implying low impact 
on HRQoL), with only a minimal rise one week after treatment (excision, curettage and 
cautery, cryotherapy or excision and flap). Therefore they concluded that BCCs cause little 
handicap.
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Generic questionnaires
Many studies in BCC and SCC patients, using multiple generic questionnaires (such as 
Short Form 36-item Health Survey (SF-36), Functional Assessment of Cancer Therapy-
General (FACT-G)), reported a general health status comparable to the normal population 
in all domains of the SF-36 [10, 14, 16]. FACT-G scores were high compared with other 
malignancies suggesting little impairment on the subscales emotional, functional, physical 
and social well-being. It only demonstrated a slight improvement in emotional well-being 
after treatment [16]. The relevance of many items was frequently questioned by the study 
participants.
Another study focused on distress and coping strategies by using the Hospital Anxiety and 
Depression Scale (HADS) and the Ways of Coping Questionnaire – Cancer Version (WOC-
CA) [17]. They reported that 19% of the NMSC patients experienced significant levels of 
distress (HADS score ≥ 13). The most often used coping strategies were behavioural escape 
avoidance and distancing.
Concluding, it is possible that the affected domains of HRQoL in KC patients are not fully 
captured by the generic questionnaires (SF-36 and FACT-G) since they show little impair-
ment whilst HADS display distress in 19% of the KC patients.
Dermatology specific questionnaires
In a cross-sectional study among 52 German patients diagnosed with AK, BCC, SCC or 
Bowen’s disease [19], the majority of the patients reported no to slight HRQoL impairment 
using the DLQI. However, a third of patients reported a moderate to large impairment, 
especially in the subscales “symptoms and feelings”, “leisure” and “daily activities”.
In a prospective US cohort study, BCC was associated with low DLQI scores indicating 
little HRQoL impairment. Four months after therapy, only the items focusing on physical 
improvement and embarrassment decreased significantly, suggesting suboptimal respon-
siveness of the DLQI. Moreover, lack of relevance of several items was mentioned by many 
participants [15, 21]. In both studies, the low scores indicate a lack of HRQoL impact or 
otherwise a poor content validity in the studied populations.
A large study among 931 patients with a history of KCs demonstrated a higher effect on 
each of the three domains of the Skindex-29 compared to a historical reference sample of 
persons without skin disease [20]. The main items responsible for this impairment were: 
‘worrying about seriousness of the skin condition’ and ‘worrying about it getting worse’ in 
the emotions subscale. The most prominent predictive factors for worse Skindex-29 scores 
were AK count, ever-use of 5-fluorouracil (5-FU) and younger age [20]. Six KC-specific 
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items were added to the Skindex-29, suggesting a possible problem with content validity. 
The topics of these items were about bother (from scars, about appearance and about 
persistence of skin condition) and worry (about treatment and that the skin condition will 
spread) and were scored similar to the Skindex items.
A prospective trial by the same group with the Skindex-29 was performed to investigate 
the HRQoL effects of developing new KCs over a 36 month course. The 6 item KC-specific 
questions used in the previous mentioned study were also used. They reported no dif-
ference in Skindex-29 or KC-item scores in patients with new KCs, in comparison to their 
own scores 12 months prior. The only exception were the KC-specific items at 12 months, 
however this was not found at the 24- or 36-month assessment [12].
A prospective cohort study using the Skindex-16 to measure HRQoL in patients undergoing 
treatment (electrodessication and curettage, excision and Mohs surgery) reported worse 
scores on the emotions domain before treatment in the Mohs surgery group [8, 11]. There 
were no significant differences in functional outcomes, but the electrodessication and 
curettage group did not improve, whereas the excision and Mohs surgery group did [9].
The newer, Rasch-reduced Skindex-17 has been used in one more recent study comparing 
the field performance of the Skindex-29 with the Skindex-17 [18]. In this study with 2487 
patients in total, 79 patients had NMSC. The mean scores in this subgroup were published 
for both questionnaires, showing a mean value of 18.2 (Skindex-29) and 19.6 (Skindex-17) 
in the symptoms domain, and a mean of 12.8 (Skindex-29) and 9.2 (Skindex-17) in the 
psychosocial domain. There was also a very high concordance between the Skindex-29 
and Skindex-17 overall [18].
Concluding, dermatology specific tools such as the DLQI and to a lesser extent the Skindex 
questionnaires lack face validity and are not specific enough to capture KC patients con-
cerns in detail.
Skin cancer specific questionnaires
Fortunately, several attempts have been made to develop skin cancer specific tools, since 
the above mentioned general and dermatology specific HRQoL instruments are not spe-
cific enough.
The Skin Cancer Index (SCI) was the first, developed after a thorough process using semi-
structured interviews (20 patients and 6 healthcare providers) for item generation in stage 
I and rating of importance by a second sample of patients for item reduction in stage II (52 
patients) [27]. The final 36 remaining items were captured within 6 domains: emotional, 
appearance, work / financial, lifestyle / recreation, social / family and physical / function-
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ing. Based on test-retest reliability, validation and sensitivity testing the authors created a 
15-item questionnaire with three domains: emotional, social and appearance [28, 29]. In 
a prospective study with 183 patients the SCI was tested in a tertiary care Mohs surgery 
clinic at initial consultation and four months after treatment. The average SCI total score 
post-surgery was 77.3 (vs. 68.3 pre surgery) and all three domain scores improved with 
treatment [21]. Paired t tests were used to assess responsiveness and showed P values 
<.001 in all three domains and in the total score. These findings were confirmed in a 
prospective study of 53 KC patients attending a plastic surgery clinic [30]. The SCI fails 
to capture one of the most reported issues in skin cancer patients; the often required 
behavioural changes (and related psychological issues) to reduce sun exposure.
The Skin Cancer Quality of Life Impact Tool (SCQOLIT) was created as a versatile question-
naire for use in nonmetastatic skin cancer (MM and NMSC) including HRQoL issues as 
mentioned before [31, 32]. The target population was patients with nonmetastatic skin 
cancer including MM patients [31]. The researchers collected data by asking 100 (50 MM 
and 50 NMSC) patients to fill in an open-ended anonymous ‘Skin Cancer Quality of Life 
Question Sheet’. The most reported themes were ‘concern about the public’s lack of 
understanding and recognition of skin cancer’, ‘awareness of the importance of avoiding 
excess sun exposure’ and ‘concern that skin cancer could spread, recur or develop’. The 
HRQoL themes were then transformed by the authors into ten items in the questionnaire. 
In a prospective study with 120 patients (60 MM and 60 NMSC) the questionnaire was 
tested and validated. It has not been used in other studies yet. One major flaw in the 
SCQOLIT is the use of multiple issues and questions combined in one item. For example, 
the 5th item; “over the last week, how much have you felt emotional, anxious, depressed, 
guilty or stressed, in respect to your skin cancer or its treatment” tries to capture five psy-
chological issues regarding two different aspects of the skin cancer in one item. Therefore, 
the interpretability of the questionnaire is insufficient. Similar to the SCI, the SCQOLIT also 
does not measure the impact of behavioural changes to reduce sun exposure.
Both the SCI and the SCQOLIT were both developed in a step-by-step approach to first 
generate and later reduce items [28, 32]. Most of the HRQoL instrument characteristics 
(validity (concept, construct and convergent), reliability, structure, responsiveness, floor 
and ceiling effects, item bias, respondent and administrative burden), as proposed by Both 
et al., apply for these instruments [33].
A recent Danish study described the development of the Actinic Keratosis Quality of Life 
(AKQoL) questionnaire focussing entirely on AK while using a similar approach as used 
in the SCI to first generate and later reduce items [27, 34]. They produced four domains 
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(functions, emotions, control and global) and 9 items. The AKQoL was tested and validated 
and is a promising instrument for use in studies comparing treatments for AK.[35]
In contrast to the before mentioned SCI and SCQOLIT, the Skin Cancer Quality of Life 
(SCQoL) questionnaire was developed and validated by using modern test theory, namely 
Rasch analysis [36]. The instrument was, however, derived from the previously developed 
AKQoL and only pre-tested in a very small sample (18 AK patients, 14 skin cancer patients) 
with the objective of distinguishing between patients with AK and those with skin cancer. 
From a content validity perspective, the above-mentioned questionnaires do not capture 
the psychological issues due to the behavioural changes often required to reduce sun 
exposure.[36, 37]
In conclusion, existing HRQoL measures are limited because they fail to capture important 
behavioral changes of KC patients, interpretability is questionable due to multiple items 
into 1 question and face and content validity are lacking. Therefore, a KC HRQoL instrument 
needed to be developed, which captures all important aspects and is easy to interpret.
Aims for this thesis
The aims of this thesis were to assess HRQoL and patient perception on disease, treatment 
and provided information in KC patients.
First we performed a review of the available literature to assess the available question-
naires (this chapter). Second, a dermatology specific HRQoL questionnaire and an existing 
disease-specific HRQoL questionnaire were used to assess the sensitivity of the question-
naires around an intensive treatment with topical imiquimod (chapter 2). The perception 
of the patients on treatment was also assessed. Since the existing questionnaires did 
not capture some important aspects of HRQoL or had major methodological flaws, we 
developed and validated the basal and squamous cell carcinoma quality of life (BaSQoL) 
questionnaire (chapter 3) and additionally validated the English translation of the BaSQoL 
(chapter 4). Finally, to assess the impact of KC diagnosis and treatment on HRQoL and to 
identify factors associated with this we performed two population based studies, the first 
focusing on the role of information provision on HRQoL (chapter 5) and the second in 
relation to treatment (chapter 6).
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Embase MEDLINE OvidSP PubMed Publisher Cochrane Central
N = 390 N = 368 N = 14 N = 8
530 abstracts Exclude duplicationsN = 250
31 articles
Inclusion criteria title/abstract:
· Nonmelanoma skin cancer or dermatology 
(Basal Cell Carcinoma, Squamous Cell 
Carcinoma)
· (HR)QOL assessment
· Any date
Exclusion criteria title/abstract:
· Language other than English
· Squamous cell carcinoma of other origin 
than skin
(n = 499)
10 questionnaires used 
in KC patients
11 additional 
articles
Generic questionnaires
· UKSIP
· SF-36
· FACT-G
Dermatology Specific questionnaires
· DLQI
· Skindex (29, 17, 16)
Disease specific questionnaires
· SCI
· SCQOLIT
· AKQoL
4 articles reporting 
QOL issues
Figure 1. Flowchart systematic search as used in ‘A review on quality of life in keratinocyte carcinoma patients’ 
G Ital Dermatol Venereol 2013 Jun;148(3):249-54.
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ABStRACt
Background/Aims
To document the impact on patient-reported outcomes and health-related quality of life 
(HRQoL) of treatment with imiquimod cream in patients with actinic keratosis (AK) and 
superficial basal cell carcinoma (sBCC).
methods
This open-label, multicenter study included AK and sBCC patients eligible for treatment 
with imiquimod 5% cream. HRQOL was measured by the Skindex-17 and the Skin Cancer 
Index (SCI) and treatment satisfaction by the Treatment Satisfaction Questionnaire for 
Medication.
Results
118 AK patients and 84 with sBCC were included. Low baseline HRQoL impairment was 
found on both questionnaires, which remained low after treatment, except for a small dip 
at the end of the application period.
Conclusion
Imiquimod 5% cream treatment has no clinically relevant HRQoL impact in AK and sBCC 
patients according to the Skindex-17 and SCI. Effect of imiquimod treatment on HRQoL 
may be limited or these questionnaires do not fully capture relevant issues, such as fear 
of recurrence.
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Patient Perception of Imiquimod Treatment for AK and sBCC
INtRODUCtION
Actinic keratosis (AK) is regarded as the first clinically relevant sign of sun induced skin 
damage. This in situ lesion is a precursor lesion for cutaneous squamous cell carcinoma 
(SCC). It is considered indicative of risk for developing SCC and basal cell carcinoma (BCC), 
approximately 0.5% per year per lesion progress into SCC.[1, 2] The incidence of cutane-
ous premalignancies and malignancies is increasing rapidly. Due to the high likelihood 
of developing multiple lesions during life, it is increasingly being considered as a chronic 
illness, i.e. “actinic neoplasia syndrome (ANS)”.[3-7]
In chronic diseases, patient reported outcomes (PRO) and health-related quality of life 
(HRQoL) are increasingly important outcomes in daily patient care. Treatment satisfaction 
is also a part of the PRO, and more applicable to diseases with multiple treatment op-
tions. In AK and sBCC, a variety of treatment options is available, including surgery, locally 
destructive procedures and non-invasive field therapies such as topical 5-fluorouracil, 
imiquimod, photodynamic therapy and ingenol mebutate.[8-10]
Imiquimod is available in the Netherlands as 5% cream (Aldara®). It acts as an immu-
nomodulator by activating Toll-like receptor (TLR)-7 which stimulates the epidermal and 
dermal dendritic cells to produce cytokines and attract natural killer cells, and enhances 
proliferation of B lymphocytes.[11] Clinical trials have shown complete clearance rates 
around 70% and partial clearance rates around 80% for AK when treated with two four-
week treatment courses of applying the cream 3 days a week.[8, 12] For sBCC the reported 
clearance rates are around 80% in a six-week treatment course, applying the cream 5 days 
a week.[9, 13]
Adverse events such as fever-like symptoms and application site reactions are common in 
imiquimod treatment due to the induced inflammatory response. These possible severe 
local and systemic reactions may have an impact on treatment response, daily life and 
treatment satisfaction. The objective of this multicenter open label study was to assess 
HRQOL and treatment satisfaction in patients with AK or sBCC treated with imiquimod.
mAteRIAL AND metHODS
Study design
This open label clinical study was conducted in two university medical centers (Erasmus 
MC University Medical Center Rotterdam and UMC Groningen) and six other non-
university hospitals across the Netherlands (Center Oosterwal Alkmaar, Amphia hospital 
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Breda, Catharina hospital Eindhoven, Reinier de Graaf hospital Delft, Diaconessen hospital 
Leiden, St. Antonius hospital Nieuwegein) between January 2009 and September 2011. 
The primary outcome was defined as the impact of treatment on dermatology-specific and 
disease-specific HRQoL in daily practice conditions. Secondary outcomes were short-term 
response rates, adverse events and treatment satisfaction. The study protocol was ap-
proved by the medical ethical committee (Erasmus MC, no. NL23594.078.08). All patients 
provided written informed consent.
Patients
Patients over 18 years of age, clinically diagnosed with one or multiple AK, or sBCC, and 
eligible for treatment (i.e. capable of performing the treatment correctly) with 5% imiqui-
mod cream were invited to participate. Biopsy was only performed if thought necessary 
by the participating dermatologist. Patients with inadequate understanding of Dutch 
language to fill in the questionnaires were excluded.
Questionnaires
The questionnaires used in this study are the Dutch version of both the Skindex-17 and 
the Treatment Satisfaction Questionnaire for Medication (TSQM).[14, 15] To assess the 
disease-specific HRQoL, the Skin Cancer Index (SCI) was used. Since there was no Dutch 
version available, we translated the questionnaire based on forward-backward transla-
tion, as recommended.[16] To suit the questionnaire for use in AK patients, we replaced 
‘skin cancer’ by ‘actinic keratosis’.
Actinic keratosis
Participants with AK were instructed to apply imiquimod 5% cream once daily in a thin 
layer to the lesion including 5-10 mm of the surrounding skin, 3 days a week for 4 weeks. 
They were asked to complete the Skindex-17 and SCI at baseline, before treatment (T=0), 
directly after 4 weeks of treatment (Tak=1) and 8 weeks after baseline (Tak=2). Questions 
concerning side effects were administered at Tak=1 and Tak=2, and the TSQM at Tak=2. The 
treating physician reported on patient history and current dermato-oncological status at 
baseline and answered questions concerning response at Tak=2 and 16 weeks after baseline 
(Tak=3). Response rates of the imiquimod therapy were assessed 16 weeks after start of 
therapy and categorized as ‘no response’, ‘partial response’ or ‘complete response’. Com-
plete response was defined as clinically observed complete clearance of the lesion, partial 
response as clinically observed decrease in size and no response as clinically observed no 
change in the lesion compared to T=0. Retreatment for another four-week course due to 
insufficient response was allowed if considered necessary by the local dermatologist.
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Superficial basal cell carcinoma
Participants with sBCC were instructed to apply imiquimod 5% cream once daily in a 
thin layer to the lesion including 5-10 mm of the surrounding skin, 5 days a week for 
6 weeks. They were also asked to complete the Skindex-17 and SCI at baseline, before 
treatment (T=0), directly after 6 weeks of treatment (TsBCC=1) and 18 weeks after base-
line (TsBCC=2). Questions concerning side effects were administered at TsBCC=1 and TsBCC=2, 
and the TSQM at TsBCC=2. The treating physician reported on patient history and current 
dermato-oncological status at baseline and answered questions concerning response at 
TsBCC=2. Response rates of the imiquimod therapy were assessed at eighteen weeks and 
categorized as ‘no response’, ‘partial response’ or ‘complete response’. These categories 
were defined similarly as in the AK group.
Statistical analysis
Continuous variables are expressed as mean and standard deviation (SD) and categori-
cal variables are described as frequencies and percentages. If the data was not normally 
distributed, median and interquartile range (IQR) are displayed.
The Friedman test was performed to compare scores of the Skindex-17 and SCI at T0, T1 
and T2. Wilcoxon signed rank tests were performed to assess the change compared to 
baseline (T0). The α-level for these tests was adjusted by using the Bonferroni correction.
The chi-squared test was used for the comparison of response rates and adverse events. 
Logistic regression was performed to calculate the p-value for trend, using adverse events 
as dependent variable and response rates as independent variable.
Pearson’s (two continues variables) and point biserial (continues and dichotomous vari-
able) correlation coefficients were used to assess correlations. Statistical significance was 
set at p < 0.05 (two-sided). Statistical analyses were performed using IBM SPSS Statistics, 
version 20 for Windows.
ReSULtS
Study population
A total of 202 patients were included in this multicenter open label trial. The study popula-
tion consisted of 118 patients with AK and 84 with sBCC. The mean age in the AK group 
was slightly higher than in the sBCC group (67 vs. 62 years). In the AK group 58% was male 
and 37% in de sBCC group. The medical history and previous treatment also differed. All 
baseline patient and lesion characteristics are shown in Table 1.
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table 1. Patient characteristics
Actinic Keratosis
N (%)
Superficial BCC
N (%)
Total number of patients 118 84
Age (years) Mean (SD) 67 (10) 62 (12)
Missing 3 (3) 5 (6)
Gender: Male 68 (58) 31 (37)
Missing 4 (3) 6 (7)
History of cutaneous malignancy or 
premalignancy:a
• None 25 (21) 26 (31)
• Actinic keratosis 79 (67) 15 (18)
• Melanoma 6 (5) 1 (1)
• Basal cell carcinoma 42 (36) 55 (66)
• Squamous cell carcinoma 13 (11) 4 (5)
• Other skin malignancy 2 (2) 4 (5)
Previous treatment with:a
• None 24 (20) 27 (32)
• Cryotherapy 75 (64) 20 (24)
• Coagulation 2 (2) 1 (1)
• Imiquimod cream 4 (3) 2 (2)
• Surgery 56 (48) 48 (57)
• 5-Fluorouracil cream 22 (18) 7 (8)
• Photodynamic therapy 18 (15) 18 (21)
Missing 1 (1) 1 (1)
Number of lesions:
• 1 29 (25) 53 (63)
• 2-4 15 (13) 25 (30)
• 5-9 34 (29) 4 (5)
• ≥ 10 36 (31) -
Missing 4 (3) 2 (2)
Locations of lesions
• Face / head / neck 78 (66) 14 (17)
• Scalp 23 (20) 1 (1)
• Torso 16 (14) 47 (56)
• Arms 19 (16) 20 (24)
• Legs 3 (3) 25 (30)
Missing 1 (1) 1 (1)
a Patients could choose multiple options, therefore the total may add up to >100%
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HRQoL
The low baseline HRQoL impairment, as measured by the Skindex-17 and the SCI, did not 
improve after imiquimod therapy. (Table 2) The impact of AK and sBCC, as measured by 
the Skindex-17, demonstrated a modest increase (indicating more impairment) in both 
the scores of the symptom and the psychosocial domains at the end of the application 
period (e.g. from 26 to 37 on a standardized scale at week 6 for sBCC patients). The change 
in the SCI was modest for both AK and sBCC (difference < 3 points on a scale from 0 to 
100). Almost all the domains and overall standardized scores were above 80 (with 100 
indicating no impairment). Except for a small dip at the end of the application period, the 
SCI standardized scores remained comparable before and after therapy.
There was no correlation between age, gender or educational level and HRQOL scores 
(p-value >0.05 for age gender and educational level). AK and sBCC patients with adverse 
events had more HRQoL impairment compared to patients without adverse events 
(p<0.05), which is a consequence of the symptom-related questions in the HRQoL ques-
tionnaires. Patients who experience more adverse events (i.e. symptoms), will score 
higher at the symptom-related questions, leading to higher overall scores, indicating more 
HRQoL impairment.
Response rates
Retreatment with another four-week course was necessary in 58% of the patients in the 
AK group due to insufficient response. Overall, complete response was achieved in 46% of 
the AK patients and 76% of the sBCC patients. Partial response in 35% of the AK patients 
and 8% of the sBCC patients. (Table 3)
When these response rates of the AK patients are linked to the percentage reporting 
adverse events, a significant trend is found (p=0.001) between the two, showing a high 
percentage of adverse events in the complete response group (74%) which decreases 
among patients with a partial response (39%) and without a response (25%). This was not 
found in the sBCC group.
Adverse events
About half of the patients using imiquimod cream reported at least some itching, redness 
and pain/burning sensation of which 26% reported it to be severe. A third of patients noted 
to have vesicles/bullae or swelling. Approximately 10-15% of all patients self-reported to 
have fever or influenza-like symptoms. The proportion of patients reporting these adverse 
events was very comparable between the AK and sBCC group. (Table 4) Overall, 6-7% of 
patients discontinued therapy due to side-effects and 5% would not use imiquimod again 
due to adverse events (5,1% of AK and 4,8% of sBCC patients).
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treatment satisfaction
Treatment satisfaction, as measured by the TSQM, showed that patients appreciated the 
convenience of imiquimod use most (>60 on a scale from 0 to 100), but the overall satis-
faction scored less than 60. The side effect domain of the TSQM scores were comparable 
AK and sBCC patients. (Figure 1) No correlation was found between treatment satisfaction 
and adverse events or previous treatment. Patients with complete response had higher 
treatment satisfaction (median TSQM overall score 61 for AK and sBCC) than those with 
partial (median TSQM overall score 54 for AK and 53 for sBCC) or without a response 
(median TSQM overall score 22 for AK and 40 for sBCC) in both groups (p<0.05).
table 3. Response rates at T=2c to imiquimod therapy
Actinic Keratosis Superficial 
BCC
1st cycle
N=118 (%)
2nd cyclea,b
N=69 (%)
Overall
N=118 (%) N=84 (%)
• No response 9 (8) 4 (6) 4 (3) 3 (4)
• Partial response 60 (51) 41 (59) 41 (35) 7 (8)
• Complete response 42 (36) 12 (17) 54 (46) 64 (76)
•  Cessation of therapy due to side 
effects
4 (3) 5 (7) 9 (8) 5 (6)
a Excluding those with complete response in 1st cycle, those who ceased therapy and missing.
b 69 / 118 needed a 2nd cycle
c response rate was assessed at 16 weeks for AK and at 18 weeks for superficial BCC
abbreviations: BCC = basal cell carcinoma
table 4. Adverse events among AK and sBCC patients treated with imiquimod cream at T=1a
Actinic Keratosis Superficial BCC
type of reaction total Intensity total Intensity
N (%) Week 4
N=118
Mild Moderate Severe Week 6
N=84
Mild Moderate Severe
Itching 58 (49) 19 (33) 24 (41) 15 (26) 38 (45) 16 (42) 14 (37) 8 (21)
Redness 61 (52) 9 (15) 23 (38) 29 (48) 41 (49) 6 (15) 17 (42) 18 (44)
Pain / Burning sensation 49 (42) 13 (27) 20 (41) 16 (33) 34 (41) 9 (27) 14 (41) 11 (32)
Squamae 42 (36) 15 (36) 23 (55) 4 (10) 17 (20) 8 (47) 7 (41) 2 (12)
Vesicles / Bullae 40 (34) 15 (38) 13 (33) 12 (30) 31 (37) 8 (26) 17 (55) 6 (19)
Swelling 37 (31) 14 (38) 16 (43) 7 (19) 23 (27) 9 (39) 14 (61) -
Other local complaints 9 (8) 2 (22) 3 (33) 4 (44) 3 (4) - 1 (33) 2 (67)
Influenza-like symptoms 16 (14) 2 (13) 7 (44) 7 (44) 11 (13) 4 (36) 6 (55) 1 (9)
Fever 11 (9) 4 (36) 2 (18) 5 (45) 9 (14) 3 (33) 4 (44) 2 (22)
Other systemic 
complaints
7 (6) - 2 (29) 5 (71) 8 (10) 1 (13) 3 (38) 4 (50)
Patients could report multiple reactions, therefore the total may add up to >100%
a T=1 was 4 weeks after treatment for AK and 6 weeks after treatment for sBCC.
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DISCUSSION
In this study, HRQoL impairment, as measured by the Skindex-17 and SCI, was low prior to 
treatment and remained low after treatment in both patients with AK and sBCC.
Our results are in line with published data. These results suggests little to moderate im-
pact on HRQoL of AK/BCC treatment or suggest that the available HRQoL instruments are 
not specific and sensitive enough to record the issues considered important in this large 
patient population.[17] The Skindex-17 is probably not specific enough to capture specific 
skin cancer patient concerns. Although the SCI was developed specifically for BCC and SCC 
patients and demonstrated impairment on the emotional and the appearance subscales 
in the validation study, in our study standardized scores (0 to 100) were all above 75.[18] 
This observation implicates that HRQoL impairment in our population (i.e. treated with 
imiquimod) is less than in patients who will have to be treated surgically, or that the SCI 
is only suitable for use in patients being treated surgically, since it was developed in a 
tertiary care Mohs surgery clinic.[19]
Responsiveness, another pivotal feature of HRQoL questionnaires, addressing the effect of 
treatment, could not be confirmed for the Skindex-17 and the SCI. In the Skindex-17 this 
can be explained by the more generic aspect of the items in the questionnaire. The SCI 
however displayed good responsiveness before and after treatment in previous studies.
[19, 20] The only treatment assessed however was surgical treatment and the lesions 
were only located in the head-neck area. Our data suggest only minimal responsiveness in 
all subscales, but not clinically relevant when considering Norman’s “rule of thumb”.[21]

 
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
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     
 

 



Figure 1. Treatment Satisfaction Questionnaire for Medication (TSQM) scores.
AK = Actinic Keratosis, sBCC = superficial Basal Cell Carcinoma, IQR = Interquartile Range
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We showed that imiquimod scored an overall satisfaction score around 60. It is considered 
a convenient therapy, but the side effects were scored lower than the overall score by the 
patients. About half had local side effects and 10-15% systemic reactions. The observed 
adverse events and response rates were comparable to the large imiquimod RCT.[13]
Application site reactions occurred similarly in both of our groups. The patient reported 
severity of these reactions are also alike, despite the different treatment regimen in the 
groups. The intensity was mostly scored as mild or moderate. These findings are in ac-
cordance with previous reports.[13, 22-24]
Strengths & Limitations
In our study, we were able to assess HRQoL, treatment satisfaction and short term re-
sponse rates in daily practice use of imiquimod 5% cream in both AK and sBCC patients. 
To our knowledge, this is the first study assessing treatment satisfaction using a validated 
tool. One previous study used a 7-point Likert scale and another an analogue scale [0-10].
[22, 25]
Unfortunately, we have no additional data on all AK and sBCC patients visiting the depart-
ment. Patient characteristics and reason for non-participation of patients who refused 
to participate in this study were not available, which hindered the judgment about the 
presence of a possible selection bias. Selection bias may have occurred if specific patient 
groups were not included in our study and those patients would have a lower or higher 
impact on HRQoL or different treatment satisfaction. For example, if older patients refused 
to participate and the impact of imiquimod on HRQoL among older patients is larger, than 
the impact of imiquimod in our study on the HRQoL would have been underestimated if 
only younger patients were included in which the impact was smaller. We deemed selec-
tion bias due to age likely because some older patients may not be capable of performing 
the treatment correctly, and therefore may have refused to participate.
CONCLUSION
In conclusion, this study showed that imiquimod 5% cream treatment has no clinically rel-
evant HRQoL impairment nor improvement after treatment in both AK and sBCC patients 
according to the Skindex-17 and the SCI. Patients report to tolerate the treatment well, 
but overall satisfaction is only around 55 to 60% in both groups. The results of this study 
also suggest that the available HRQoL instruments are not specific and sensitive enough to 
capture the issues considered important in skin cancer patients.
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ABStRACt
Health-related quality of life (HRQoL) is important in basal cell carcinoma (BCC) and squa-
mous cell carcinoma (SCC) management. Disease-specific questionnaires exist, but with 
important shortcomings. Our goal was to develop and validate a questionnaire suitable 
for use in all BCC and SCC patients. In a four-phase trajectory, a preliminary questionnaire 
was created and tested population-based (1173 patients). The questionnaire was reduced 
using exploratory factor analysis and item response theory. Individual item performance 
was assessed using classical test theory. 721 patients completed the questionnaire. The 
number of items was reduced to 16, covering five scales. Confirmatory factor analysis 
showed a good fit. Cronbach’s αs (range 0.67 – 0.82) were reasonable to high with good 
internal consistency. The Basal and Squamous cell carcinoma Quality of Life questionnaire 
has good face, content and construct validity. It is useful in the wide range of BCC and SCC 
patients and captures HRQoL impact in different timeframes.
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INtRODUCtION
The use of patient-reported outcome measures (PROMs) and more specifically health-
related quality of life (HRQoL) in dermatology patients has dramatically increased over 
the past decades. It is now an essential outcome for clinical studies and in daily practice, 
especially in chronic inflammatory skin diseases [1, 2]. In skin cancer, the use of PROMs 
and HRQoL has only been used over the past two decades and most of the focus has 
been on melanoma [3]. Since the incidence of basal cell carcinoma (BCC) and squamous 
cell carcinoma (SCC) is increasing rapidly [4-6], the need for PROMs assessment including 
HRQoL is warranted to evaluate individual and global disease burden. Generic, cancer 
or even melanoma specific HRQoL instruments are neither content specific nor sensitive 
enough to detect the impact of the rarely life-threatening BCCs and SCCs that are most 
often treated by conventional excision. A specific issue for keratinocytic cancers is that 
patients are likely to develop multiple carcinomas and also actinic keratosis (AK) (so called 
actinic neoplasia syndrome) and that they can check their skin constantly [7].
Measurement of HRQoL in BCC patients has occurred in several studies, using generic, 
cancer related and dermatology specific questionnaires, all reporting little to no impact 
[7-13].
A few disease specific questionnaires have been developed, but these have several impor-
tant shortcomings. The Skin Cancer Index (SCI) is developed and tested only in a tertiary 
care Mohs surgery clinic and therefore only suitable for use in a selected population [14, 
15]. The Skin Cancer Quality of Life Impact Tool (SCQOLIT) is developed as a tool for non-
metastatic skin cancer patients [16]. A limitation of the SCQOLIT is the addressing of five 
psychological issues regarding two different aspects in one item. In contrast to the SCI 
and the SCQOLIT , the Skin Cancer Quality of Life Questionnaire (SCQoL) was developed 
and validated with modern test theory, namely Rasch analysis [17]. This instrument was 
however derived from the previously developed Actinic Keratosis Quality of Life question-
naire (AKQoL) and pre-tested in a small sample (18 AK patients, 14 skin cancer patients) 
with the objective to distinguish the difference between AK and skin cancer patients [18]. 
From a content validity perspective, we feel that the before mentioned questionnaires do 
not to capture the psychological issues due to the often required behavioural changes to 
reduce sun exposure [19].
The objective of this study is to create and validate a HRQoL questionnaire suitable for BCC 
and SCC patients addressing relevant issues for patients and healthcare providers using 
different methodological approaches.
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metHODS
Study design
The BCC and SCC specific HRQoL questionnaire was prepared and developed following 
the European Organisation for Research and Treatment of Cancer (EORTC) QOL group 
guidelines as much as possible [20-22]. However, the questionnaire is not an EORTC QOL 
group product and was not developed internationally. The development was conducted 
in four phases.
Phase I:
The main goal of phase I was to generate an extensive list of HRQoL issues relevant to 
BCC and SCC patients. One focus group meeting to discuss and generate HRQoL issues 
was facilitated by two independent psychologists with no in-depth skin cancer knowledge. 
The group consisted of 10 BCC and/or SCC patients with different types and numbers 
of tumours, treatments, gender and age. The audio recording of the focus group was 
analysed by RWS to extract as much issues as possible without formal transcribing. Exten-
sive literature searches through PubMed (Table S4) and semi-structured interviews with 5 
healthcare providers (HCP) provided additional issues [23].
The issues were discussed in an expert panel including dermatologists, psychologists and 
epidemiologists to identify the relevant disease-specific domains and issues (figure 1).
The remaining issues were presented to HCP (dermatologists, plastic surgeons, ophthal-
mologist, head-neck ENT surgeon, general practitioners) and patients for feedback and 
cognitive debriefing. They were also asked to rate the issues for relevance from 1 (not 
relevant) to 4 (very relevant) on a Likert scale (relevance rating). Issues with relevance 
mean score ≥ 1.5 were selected for priority rating. HCP and patients were asked to select 
15 core issues to be included in the questionnaire (priority rating). Priority ratings of ≥ 30% 
were scored in het HCP group and ≥ 20% in the patient group. Issues scoring ≥ 3 criteria 
were included in the final issue list [20].
Phase II:
The final issue list was rephrased into questions compatible with the EORTC QLQ-C30 in 
terms of format of response categories [24]. The time frame of the questions was divided 
into three parts (‘since diagnosis’, ‘time between diagnosis and treatment’ and ‘during the 
past week’) since the items fitted different timeframes.
Phase III:
The item questionnaire was pretested in 16 patients.
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Phase IV:
The questionnaire was field tested in 1,173 patients selected from the Netherlands Cancer 
Registry, as collected by Comprehensive Cancer Centre Netherlands, location Eindhoven. 
Patients were selected if they were diagnosed in one of the nine participating hospitals or 
clinics during the past twelve months before the field testing. The aim of the field testing 
was to determine scale structure, reliability, validity and to reduce the number of items. 
The Skindex-17 and the QLQ-C30 were also administered.
Statistical analysis
Descriptive statistics (means and percentages) were used in phase II to calculate relevance 
and priority ratings of the issue list and in phase IV to describe the patient characteristics. 
Type of BCC was grouped as multifocal (8091 of the International Classification of Disease 
for Oncology [ICD-O3] ), infiltrating (8092, nodular (8097), other (8090,8093,8094,8095). 
Aforementioned analyses were performed in IBM SPSS Statistics for Windows, Version 
21.0 (Armonk, New York: IBM Corporation).
After phase IV, the components were determined using principal component analyses 
(PCA) with varimax rotation. The number of components was determined with a Monte 
Carlo PCA for parallel analysis [25]. We ran two PCAs, one with complete cases and one 
with mean substitution, with one missing at most. Items with loadings of >0.40, were 
selected for Item Response Theory (IRT) [26]. IRT was used to select a minimum number 
of the best discriminating items covering the whole range of the latent traits.
For IRT analysis, we applied the two parameter latent trait model (2PL-ltm) [27] of the ltm 
package in R version 3.0.0. The 2PL-ltm program results in an ordering of the items on a 
given trait or component and supplies a discrimination value for each item. The 2PL-ltm 
program needs binary items as input. By collapsing the four answer category to binary 
items, some loss of information is induced. This method is preferred over multicategory 
models, because these do not provide an ordering of the items.
The original categories were “not at all”, “a little”, “quite a bit “ and “very much”. For the 
majority of items the median was between the first and second category, and for this 
reason we dichotomized between “not at all” and “a little” or more.
The items were selected on basis of their position on the relevant trait or component 
and their discriminative value. As we postulated an absolute maximum of five items per 
subscale, we divided the range between the lowest and highest position by five, and we 
choose from each of these intervals the item with the highest discriminative value. We 
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checked the unidimensionality of the remaining items with the “unidim” test of the ltm 
package.
After the item reduction by the 2PL-ltm model, item performance features as used in Clas-
sical Test Theory (CTT) were tested. The definitions of the features are presented in Table 
S5 [28, 29]. Descriptive statistics were used to test item difficulty (missing responses) and 
response distribution. Spearman’s correlation coefficients were calculated for item-test 
and item-rest correlation, and also to test item discriminant validity. Internal consistency 
was tested via Cronbach’s α coefficients. Stepwise regression was performed in order to 
check the percentage of variance explained by the items in a subscale. The multitrait-
multimethod correlation matrix was used to assess convergent and discriminant validity.
The resulting factors were also tested with oblique confirmatory factor analyses. We ap-
plied two analyses, a complete cases analysis and a maximum likelihood analysis with 
missing values. We evaluated the fit indices according to the recommendations of Kline, 
Hu & Bentler and Brown[30-32]. The correlations between the subscales were reported. 
The confirmatory factor analyses were performed with STATA version 14.1 (College Sta-
tion, Texas 77845 USA). All P-values were two sided and considered significant if α <0.05.
ReSULtS
Phase I-IV:
The focus group meeting resulted in 63 issues, that were extended to 108 issues after 
literature searches (Table S4) and HCP interviews (Figure 1). After an expert consensus 
meeting 51 issues were eliminated from the list due to overlap of the issues, questions 
concerning information about the disease, cancer generic issues or other problems that 
were considered outside of the domain of HRQoL.
The remaining 57 issues were rated (mean scores, range, relevance and priority rating) 
by 42 patients (mean age of 70 years, 1-30 years since diagnosis, 27 BCC, 5 SCC and 10 
diagnosis unknown to the patient) and 15 HCP (7 dermatologists, 1 plastic surgeon, 1 head 
neck ENT-surgeon, 1 ophthalmologist, 1 radiation oncologist and 4 general practitioners) 
and resulted in the removal of the 24 issues with lowest relevance and priority ratings 
(Figure 1).
The remaining 33 issues were constructed into a provisional 33 item questionnaire (Table 
S1)
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This provisional questionnaire was reviewed by 16 patients for readability, clarity of the 
items and overlapping of the items and none of the items were excluded or rephrased.
The field testing was performed by selecting 1,173 BCC and SCC patients from 9 hospitals. 
The response rate was 61% and 721 patients completed the questionnaire. (Table 1) Of all 
respondents 85% had BCC and 15% had SCC.
The data contained 582 complete cases, 63 cases with one missing value and 76 cases with 
more missing values.
Focusgroup 
meeting
10 patients
63 issues
108 issues
Issue 
questionnaire
57 issues
Literature review 
and HCP 
interview
Expert consensus 
meeting: 51 dropout
Item 
questionnaire
33 items
Cognitive Debriefing and Relevance / Priority Rating 
Scoring issues by relevance (42 patients & 15 HCP): 
24 dropout with mean relevance score <1.5
Constructing 
issues into items
1
2
Item 
questionnaire
33 items
Pre-testing
(16 patients)3
Phase
4
Population 
based approach
1173 patients
721
respondents
264 
non-respondents
188 
Unverifiable 
addresses
BCC & SCC patients 
from 9 hospitals
19 - overlap
11 - disease information 
12 - cancer generic
9   - other
Figure 1. Questionnaire development phases.
HCP = Health Care Professional, BCC = Basal Cell Carcinoma, SCC = Squamous Cell Carcinoma.
Phase number as described by the EORTC QOL group guidelines.
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table 1. Patient Characteristics
Respondents Non-respondents Unverifiable addresses p-value
total number of patients (N) 721 264 188
Sex (column%) (%) (%) 0.0063
male 51 37 49
Female 49 63 51
Age
mean, SD 67.3, 11.8 71.4, 13.5 61.3, 15.1 <0.0001
median, IQR 68, 15 74.5, 16 61.5, 22.5
<39 1 2 9 <0.0001
40-49 8 7 16
50-59 14 9 21
60-69 31 18 22
70-79 32 33 18
80+ 14 31 13
SCC (%) 15 16 9 0.0560
Socioeconomic status
Low 17 22 13 <0.0001
Intermediate 28 29 20
High 29 31 18
Institute 3 4 4
Unknown 23 13 46
Location of tumour
Face 78 78 85 0.1000
Other 22 22 15
Other skin tumours*
multiple BCC 16 19 11 0.1000
multiple SCC 9 7 6 #
mm 0 0 1 #
Other 0 0 0 #
the following variable is only available for BCC
BCC (N) 613 222 171
type BCC (column%) (%) (%)
multifocal 11 8 9 0.070
Infiltrating 18 22 15
Nodular 64 65 65
Other 7 4 12
* patients can have combinations
# No statistical test performed due to low numbers
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Principal component analyses
The two PCAs (complete cases and with one missing included) both resulted in six com-
ponents, with the same items loading. Items 23 and 24 formed a separate component, 
and at face value these items are nearly identical. Leaving out one of them resulted in five 
components. Item 24 had a higher factor loading than item 23, for this reason item 23 
was removed from the analyses. Only item 5 was not eligible, because it had a component 
loading lower than 0.40.
The five components were labelled as: Worries (8 items, α=0.87), Appearance (7 items, 
α=0.84), Behaviour (7 items, α=0.85), Diagnosis & Treatment (5 items, α=0.84) and Other 
people (4 items, α=0.79) (Table 2).
table 2. Subscales and item characteristics.
missing 
values
Principal
component 
loading
2PL-ltm solution Selected
BaSQoL 
items
Unidim
p-valuePosition Discrimination
Worries α = 0.82 0.0297
19 2 .764 0.013 2.609 10 ●
17 1 .724 -0.404 3.056 9 ●
25 0 .696 0.249 2.079 12 ●
26 0 .665 -0.164 2.206
21 2 .646 0.827 2.472 11 ●
28 0 .630 -0.458 2.357
18 1 .626 -0.219 2.247
24 1 .482 -0.115 0.619
10 2 .401 0.035 1.112
Appearance α = 0.71 0.6733
33 0 .787 1.239 5.025 15 ●
31 1 .779 1.151 4.414
29 0 .770 1.144 3.987
22 2 .725 1.008 3.389 13 ●
30 3 .661 1.253 3.06
15 1 .580 *
32 9 .459 1.981 2.251 14 ●
Behaviour α = 0.79 0.6931
9 0 .838 0.162 3.985 4 ●
4 7 .763 0.212 2.357
6 1 .760 0.028 2.479
1 1 .748 -0.099 2.846 1 ●
2 2 .741 0.296 2.79 2 ●
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Item response analyses
The position on the components and discrimination values resulting from the 2PL-ltm 
analyses are presented in Table 2. On basis of these values the item set was reduced 
from 32 to 16 items. The characteristic curves of the selected items are presented in 
Figure 2. The “Worries” and “Behaviour” subscales retained 4 items (αs 0.79-0.82), the 
“Appearance” and “Diagnosis & Treatment” subscales retained three items (αs = 0.71-
0.78) and the “Other people” subscale retained 2 items (α = 0.67). The unidim p-value for 
the 4 selected items of “Worries” was significant (p=0.03), indicating that this subscale 
was not sufficiently unidimensional. This lack of unidimensionality was caused by item 
21. However, the unidim p-value of all 9 items was 0.38 indicating that all 9 items (includ-
ing 21) belonged to an unidimensional subscale. We decided to include the item in the 
final questionnaire because we considered it to be a conceptually important aspect and 
because of the marking of the scale of the highest position on the latent trait. Item 15 in 
the “Appearance” prevented the program to converge. Inspection of this item showed 
that it also loaded (0.37) on the “Diagnosis & Treatment” subscale, and thus violated the 
unidimensionality assumption. It was decided to delete this item from the analyses. After 
this the unidim test was insignificant for the subscales appearance, behaviour, diagnosis 
& treatment and other people, indicating that the unidim assumption has been met for 
these subscales.
table 2. Subscales and item characteristics. (continued)
missing 
values
Principal
component 
loading
2PL-ltm solution Selected
BaSQoL 
items
Unidim
p-valuePosition Discrimination
3 5 .568 0.748 1.297 3 ●
5 1 .349
Diagnosis & 
treatment
α = 0.78 0.7426
12 7 .797 0.34 5.472 7 ●
14 2 .745 0.624 2.146
13 1 .686 0.654 2.381
11 1 .610 -0.17 1.955 6 ●
16 2 .509 -0.942 2.288 8 ●
Other People α = 0.67 1.000
8 2 .809 -0.403 2.362 5 ●
7 1 .790 -0.491 2.299
27 2 .705 0.130 3.624 16 ●
20 0 .572 0.048 2.017
* Item 15 prevented the program to converge, this items also had a high loading on the treatment component 
(0.371). Preliminary questionnaire item numbers are displayed in the first column (Table S1).
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The resulting 16 item questionnaire was named Basal and Squamous cell carcinoma Qual-
ity of Life (BaSQoL) questionnaire. (Table S2)
Classical test theory
The eight CTT item performance features of the newly constructed questionnaire showed 
that 7 out of 16 items showed only one suboptimal feature and one showed two subop-
timal performance features (Table 3). From a CTT perspective, the overall performance of 
the BaSQoL is therefore considered as good. There was no significant correlation with the 
subscales of the Skindex-17 and the QLQ-C30 suggesting different issues were captured.
Confirmatory Factor Analyses
Both the complete cases and the maximum likelihood with missing vales (MLMV) had 
acceptable to good misfit scores (RMSEA and SRMR) and good goodness of fit (CFI and TLI)
(Table 4). The correlations between the subscales were generally low and there were only 
small differences between the two analyses. (Table S3).
translation
The original Dutch version of the BaSQoL was translated into English by forward-backward 
translation [22]. (Table S1)
table 3. Item performance of the BaSQoL questionnaire
BaSQoL subscales
Behaviour Other 
People
Diagnosis &
treatment
Worries Appearance Other 
People
BaSQoL item number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Item performance features
Item difficulty
Response distribution • • •
Item-test correlation
Item-rest correlation
Item discriminant validity
Item complexity
Internal consistency • •
Stepwise regression • • • •
Provisional 33 item 
questionnaire number
1 2 3 9 8 11 12 16 17 19 21 25 22 32 33 27
• Indicates suboptimal performance in a given item feature. Definition of suboptimal performance in Table S5.
Item numbers displayed are the final BaSQoL item numbers (Table S2)
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Scoring
The individual items are scored from 0 to 3, in which 0 represents no impact and 3 very 
high impact. The mean score per subscale is calculated as a scale score. A minimum of 50% 
of the questions within the subscale has to be answered to calculate the subscale score.
DISCUSSION
The BaSQoL questionnaire has been developed methodologically by following the EORTC 
QOL group guidelines as much as possible [20-22] and assesses the relevant dimensions of 
HRQoL in BCC and SCC patients.
The content of the BaSQoL questionnaire shows some overlap with items from the ex-
isting questionnaires for skin cancer, such as cancer recurrence or spreading, concerns 
about scarring and sun behaviour. But the BaSQoL captures a broader spectrum of the 
issues relevant in BCC and SCC patients such as treatment and diagnosis related issues 
and long-term behavioural changes [14, 16, 17]. Since our questionnaire was developed 
and validated in a large Dutch patient sample by using a population based approach, we 
consider it to be representative for use in the wide range of BCC and SCC patients.
Since patients were extensively involved in the whole process of the development, the 
questions are representative and in the terminology as used by the patients.
By combining the use of modern IRT and CTT analyses we aimed to create a questionnaire 
with optimal psychometric properties. Therefore the BaSQoL has good face, content and 
construct validity.
table 4. Fit indices Confirmatory Factor Analysis
Complete cases mLmV Recommended 
Kline
Recommended 
Hu & Bentler
Recommended
Brown
measures of misfit:
RMSEA 0.050 0.053 <0.05 ± 0.06 <0.05 / <0.08*
SRMR 0.042 -- <0.10 ± 0.08 <0.08
Goodness of fit:
CFI 0.958 0.956 >0.90 >0.95
TLI 0.947 0.944 >0.90 ± 0.95 >0.95
MLMV - maximum likelihood with missing values RMSEA - root mean squared error of approximation
CFI - comparative fit index TLI - Tucker-Lewis index
SRMR - standardized root mean squared residual * <0.05 – good, <0.08 reasonable
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The use of the different time frames in our questionnaire is also a unique feature. Patients 
noted a difference in behaviour before and after the initial diagnosis. Therefore the impact 
of this behavioural change is measured in the first part of the BaSQoL. The second part of 
the BaSQoL concerns the period of diagnosis and treatment. This, usually short, timeframe 
has a high impact on patients HRQoL. This subscale is suitable for assessing the patient’s 
experience of this specific period in order to manage anxiety in the process in case of 
new tumours and, in general, to optimize patient care. The final part of the questionnaire 
addresses the impact of the skin cancer during the past week. Since BCC and SCC are being 
considered as more chronic diseases, addressing the relevant issues at the right moment 
is important.
The preliminary validation of the BaSQoL has also been established by this study. 
Cronbach’s αs of the reduced subscales remained reasonable, taking into account that 
a reduction in the number of items generally leads to lower α [33, 34]. The subscales 
are psychometrically robust, displaying excellent item performance and a good fit in 
the confirmatory factor analysis. As the BaSQoL measures different aspects of HRQoL, it 
showed no significant correlation with the subscales of the Skindex-17 and the QLQ-C30 
confirming divergent validity. Unfortunately, none of the previously developed BCC or SCC 
specific questionnaires were included in this study because there are no validated BCC or 
SCC specific questionnaires available in Dutch and we intended to minimize respondent 
burden and increase the response rate. A validation study of the English version of the 
BaSQoL is underway. Construct validity by comparing to the validated SCI, test-retest 
stability and responsiveness to change will be addressed in this study. Other important 
features to increase interpretability such as categorization of scores and minimally clinical 
important difference remain to be determined.
Item 21 (BaSQoL nr 11) ‘Were you uncertain about the future?’, that violated the unidim 
assumption of the worries subscale, also had a suboptimal response distribution (Table 
3). The confirmatory factor analysis however, showed a good fit. This item reflects a more 
generic aspect than the other items in the subscale and it had far the highest position on 
the latent trait for this reason and because of the conceptual general intent of the item we 
decided to maintain it within the questionnaire.
In summary, the BaSQoL has good face, content and construct validity. The BaSQoL is 
representative for use in the wide range of BCC and SCC patients and captures HRQoL 
impact in different time periods. Therefore we consider the BaSQoL as a useful tool to 
capture HRQoL impact in future studies.
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table S1. Provisional item list
Number Item
1 Does it bother you to be careful about your behaviour in the sun? ●
2 Does it bother you to use more sunscreen (cream, spray, etc.)? ●
3 Does it bother you to check your skin for skin cancer? ●
4 Does it bother you to adjust your vacation to avoid the sun?
5 Do you feel that you have to avoid direct sunlight?
6 Does it bother you to wear certain clothing or a hat to protect you from the sun?
7 Do you feel that you should warn others for the sun?
8 Do you feel that you have to encourage others to get their skin checked? ●
9 Does it bother you to have to protect your skin from the sun? ●
10 Did you have the feeling having no control over your skin cancer?
11 Were you worried about the period between diagnosis and treatment? ●
12 Were you afraid of the treatment? ●
13 Were you worried about (possible) side-effects of the treatment?
14 Were you worried about the anaesthetic injections?
15 Were you worried about scarring?
16 Were you frightened by the word cancer? ●
17 Were you afraid to get skin cancer on multiple body sites? ●
18 Were you worried that the skin cancer would come back at the treated area?
19 Were you worried about skin cancer spreading to other parts of the body? ●
20 Were you worried about family members getting skin cancer?
21 Were you uncertain about the future? ●
22 Were you worried that you would be less attractive? ●
23 Was your skin itching at the skin cancer area?
24 Was your skin sensitive at the skin cancer area?
25 Were you worried about other skin disorders? ●
26 Were you insecure about not being able to recognise the signals of skin cancer?
27 Were you worried about other people’s skin? ●
28 Were you worried about the severity of skin cancer?
29 Were you ashamed of the scar(s)?
30 Did the questions by others about your scar(s) bother you?
31 Were you worried about whether your scar(s) could be covered?
32 Did it bother you to adjust your clothing in order to cover your scars and spots? ●
33 Did you feel less attractive? ●
● These items were translated from Dutch through forward/backward translating and are included in the final ques-
tionnaire.
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table S2. Basal and Squamous cell carcinoma Quality of Life questionnaire
the following questions are about the influence of skin cancer on your daily life
Since the skin cancer diagnosis, Not 
at all
A 
little
Quite 
a bit
Very 
much
1. Does it bother you to be careful about your behaviour in the sun? ⎕ ⎕ ⎕ ⎕
2. Does it bother you to use more sunscreen (cream, spray, etc.)? ⎕ ⎕ ⎕ ⎕
3. Does it bother you to check your skin for skin cancer? ⎕ ⎕ ⎕ ⎕
4. Does it bother you to have to protect your skin from the sun? ⎕ ⎕ ⎕ ⎕
5. Do you feel that you have to encourage others to get their skin checked? ⎕ ⎕ ⎕ ⎕
When you think back to the time of diagnosis and treatment, Not 
at all
A 
little
Quite 
a bit
Very 
much
6. Were you worried about the period between diagnosis and treatment? ⎕ ⎕ ⎕ ⎕
7. Were you afraid of the treatment? ⎕ ⎕ ⎕ ⎕
8. Were you frightened by the word cancer? ⎕ ⎕ ⎕ ⎕
During the past week, Not 
at all
A 
little
Quite 
a bit
Very 
much
9. Were you afraid to get skin cancer on multiple body sites? ⎕ ⎕ ⎕ ⎕
10. Were you worried about skin cancer spreading to other parts of the 
body? ⎕ ⎕ ⎕ ⎕
11. Were you uncertain about the future? ⎕ ⎕ ⎕ ⎕
12. Were you worried about other skin disorders? ⎕ ⎕ ⎕ ⎕
13. Were you worried that you would be less attractive? ⎕ ⎕ ⎕ ⎕
14. Did it bother you to adjust your clothing in order to cover your scars and 
spots? ⎕ ⎕ ⎕ ⎕
15. Did you feel less attractive? ⎕ ⎕ ⎕ ⎕
16. Were you worried about other people’s skin? ⎕ ⎕ ⎕ ⎕
Scoring of the items 0 1 2 3
table S3. Correlations between subscales.
Worries Appearance Behaviour
Diagnosis & 
treatment
Other 
People
Worries 0.11 0.15 0.33 0.20
Appearance 0.14 0.08 0.13 0.04
Behaviour 0.15 0.09 0.16 0.09
Diagnosis & treatment 0.33 0.16 0.15 0.17
Other People 0.20 0.06 0.09 0.17
Lower triangle complete cases, upper triangle maximum likelihood with missing values (MLMV).
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table S4. Keywords used in PubMed searches
quality of life
health-related quality of life
basal cell carcinoma
squamous cell carcinoma
non-melanoma skin cancer
table S5. Definitions of item performance features used in classical test theory
Item Item performance 
feature
Definition
1 Item difficulty Proportion of missing scores among the 721 respondents. Item difficulty 
was considered high if 10% or more of scores were missing.
2 Response distribution The proportion of patients who responded to each item with the same 
response was determined. An item was described as having a poor 
distribution if > 70% of patients had chosen the same response.
3 Item–test correlation The Spearman’s correlation coefficients (r) of each item with its subscale 
were calculated. If the r of an item differed > 0,1 with the r of the other 
items in the subscalea, it was considered suboptimal.
4 Item–rest correlation The Spearman’s correlation coefficients (r) of each item with the sum of 
the other items in that subscalea were calculated. Suboptimal item–rest 
correlation was defined as r < 0,20
5 Item discriminant 
validity
We compared the item–rest correlation coefficients with the correlation 
coefficients of an item with the other subscalesa. If the former equalled 
or was smaller than the latter, an item was defined as having poor 
discriminant validity.
6 Item complexity We investigated the factor loadings in a factor analysis for each item. 
Suboptimal complexity was said to exist if the highest loading of an item 
was < 0,40 or if the difference between the loadings on different factors 
was < 0,10.
7 Internal consistency For each subscale, the Cronbach’s α was calculated. If α < 0,70, the internal 
consistency was considered suboptimal for each subscale’s item.
8 Stepwise regression For each subscale, a forward stepwise regression analysis was performed. 
If an item entered the model after 90% or more of the variance of that 
subscale was explained it was considered suboptimal.
a Subscales derived from the principal component analysis were used.
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ABStRACt
Background: Keratinocyte carcinomas (KC) impact patient quality of life (QoL). There is a 
need for validated QoL instruments specific to KC. The Basal and Squamous Cell Carcinoma 
Quality of Life (BaSQoL) questionnaire was developed to comprehensively measure issues 
of importance to patients with KC.
Objective: To validate and characterize the BaSQoL questionnaire for QoL measurement 
following diagnosis and treatment of KC.
Methods: This was a prospective, observational study. Patients with basal or squamous 
cell carcinoma were asked to fill out BaSQoL, Skin Cancer Index (SCI), and Hospital Anxiety 
and Depression Scale (HADS) questionnaires. Descriptive statistics and classical test theory 
were used to assess validity.
Results: 187 subjects enrolled in this study: 122 with BCC and 65 with SCC. 171 subjects 
(91.4%) completed questionnaires at all three time points; 16 patients (8.6%) were lost to 
follow up. Overall performance using classical test theory was good, with good internal 
consistency (Cronbach’s s 0.63-0.80). BaSQoL subscales were strongly correlated with 
subscales of the SCI, demonstrating convergent validity, and weakly correlated with HADS, 
showing divergent validity.
Conclusion: The English language version of BaSQoL has good face, content, and construct 
validity. This study validates BaSQoL for use in English-speaking patients with BCC and SCC.
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INtRODUCtION
The keratinocyte carcinomas (KC), basal and squamous cell carcinoma (BCC, SCC), severely 
impact patient quality of life (QoL). [1] Patients may suffer from pain, bleeding, social 
embarrassment, and anxiety surrounding the diagnosis of cancer. Objective and accurate 
tools to measure these experiences and document the impact of KC are necessary. [2] 
General QoL tools, such as the Hospital Anxiety and Depression Scale, are not targeted 
towards skin disease. Within the field of dermatology, the patient experience of skin 
cancer is different from that of inflammatory skin disease. Skin-targeted quality of life 
questionnaires such as the Dermatology Life Quality Index (DLQI) are not specific enough 
to demonstrate significant quality of life impairment in patients with skin cancer, and 
show little to no improvement in quality of life after treatment. [3,4] Skindex, another 
general dermatologic questionnaire, is not specific enough to measure the impact of KC 
on quality of life. [5] More targeted questionnaires such as the Skin Cancer Index (SCI) and 
the Skin Cancer Quality of Life Impact Tool (SCQOLIT) have advanced the field but have 
limitations. [6,7] For example, neither captures one of the most reported issues in skin 
cancer patients—the necessary behavioral changes regarding sun exposure. [8] In addi-
tion, the SCI does not capture anxiety about the treatment itself, other than scarring. [6] 
Finally, neither tool addresses the full spectrum of dermatologic issues such as the burden 
of frequent skin checks, triggering worries about other skin diseases, and the behavior 
change necessary to prevent future skin cancers. [4, 6-9]
The Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) questionnaire was 
developed through a rigorous multi-phase process to comprehensively measure prob-
lems specific to patients with keratinocyte carcinomas, such as fear of scars and coping 
mechanisms, worries about subsequent skin tumors, and the burden of sun protective 
behavior. [8,10] As described previously, topics in the questionnaire were generated 
through exhaustive patient focus groups led by independent psychologists and semi-
structured interviews with healthcare providers. These items were then reviewed by an 
interdisciplinary expert panel (including dermatologists, dermatologic surgeons, plastic 
surgeons, general practitioners, ophthalmologists, and head-neck ear nose and throat 
(ENT) surgeons) then presented to patients for feedback. Patients and physicians were 
asked to rate items for inclusion in the study. Finally, the questionnaire was field tested 
in 1,173 patients selected from the Netherlands Cancer Registry and the questionnaire 
was reduced using exploratory factor analysis and item response theory. In this study, we 
validate the English translation of the BaSQoL, compare its performance to the SCI and 
HADS, and demonstrate the utility of BaSQoL in measuring quality of life in patients with 
skin cancer before and after surgical treatment.
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metHODS
The study was conducted from July 1, 2017 to June 30, 2018. Study data were collected 
and managed using Research Electronic Data Capture (REDCap) tools hosted at University 
of California, San Francisco (UCSF). [11] A consecutive sample of patients with the diagno-
sis of SCC or BCC and scheduled for treatment in the UCSF Dermatologic Surgery center 
were approached for voluntary participation. Demographic and clinical information, 
including age, sex, contact information, tumor type, tumor size, tumor location, history of 
skin cancer, and treatment plan were collected. Participants were not compensated. The 
UCSF Institutional Review Board approved the study and all participants provided written 
informed consent.
The original BaSQoL questionnaire consisting of 16 questions written in Dutch was trans-
lated to English using forward-backward translation. [12,13] The BaSQoL consists of 5 
subscales (behavior, diagnosis & treatment, worries, appearance and other people) scored 
from 0 to 3, with higher scores indicating poorer QoL. Participants were asked to fill out 
this questionnaire one week before their treatment (T0), four weeks after treatment (T1), 
and five weeks after treatment (T2). Additionally, participants were asked to complete the 
Skin Cancer Index (SCI) and the Hospital Anxiety and Depression Scale (HADS) one week 
before treatment (T0). The SCI consists of three subscales (emotional, social, appearance) 
with standardized score ranges from 0 to 100, with higher scores indicating higher QoL. We 
hypothesized high correlations between comparable subscales of the SCI and the BaSQoL 
(convergent validity). The HADS consists of two subscales (anxiety and depression) with 
scores ranging from 0 to 21, with higher scores indicating poorer QoL. The HADS was 
included to demonstrate divergent validity.
We aimed to include at least 100 patients with BCC and 50 with SCC in order to include 
sufficiently large samples of both types of KC, recognizing that BCC is the more common 
tumor. A formal sample size calculation was not performed. Classical test theory is a 
framework for evaluating the reliability of items in a questionnaire. Eight performance 
features (item difficulty, response distribution, item-test correlation, item-rest correla-
tion, discriminant validity, item complexity, internal consistency, stepwise regression) 
were tested for each item on the BaSQoL (Table S1). Descriptive statistics were used to 
test item difficulty (missing responses) and response distribution. Spearman’s correlation 
coefficients were calculated for item-test and item-rest correlation, and to test item dis-
criminant validity. Internal consistency was tested via Cronbach’s α coefficients. A forward 
stepwise regression was performed for each subscale in order to check the percentage 
of variance explained by the items in a subscale. The multitrait-multimethod correlation 
matrix was used to assess convergent and discriminant validity. We accounted for multiple 
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hypothesis testing where appropriate by correcting p-values using the false discovery rate 
(FDR) calculated by the Benjamini-Hochberg procedure. [14] In order to test the stability of 
BaSQoL responses over time, T1 and T2 responses were compared using a two-way mixed 
effect model to calculate the intraclass correlation coefficients. Analyses were performed 
in IBM SPSS Statistics for Windows, Version 21.0 (Armonk, New York: IBM Corporation).
ReSULtS
A total of 187 subjects enrolled in this study: 122 with BCC and 65 with SCC. 171 subjects 
(91.4%) completed questionnaires at all three time points; 16 patients (8.6%) were lost to 
follow up (Figure 1). The mean age of respondents was 67 and 59% were male (Table 1). 
Tumors were more likely to be located on the head and neck (84%). Most patients had a 
previous history of skin cancer (63%).
After diagnosis, 
before treatment
T0
N=187
Questionnaire 
administration:
 BaSQoL
 SCI
 HADS
4 weeks 
after treatment
T1
N=174
Questionnaire 
administration:
 BaSQoL
5 weeks
after treatment
T2
N=171
Questionnaire 
administration:
 BaSQoL
MMS or 
Excision
Patients with BCC or SCC scheduled for treatment at UCSF Dermatologic Surgery center
Figure 1. Study Design and Patient Flow Diagram. Patients with the diagnosis of SCC or BCC and scheduled for 
treatment in the UCSF Dermatologic Surgery center were approached for voluntary participation. Participants 
were asked to fill out BaSQoL, HADS, and SCI one week before their treatment (T0). They were then asked to 
complete BaSQoL four weeks after treatment (T1), and five weeks after treatment (T2).
table 1. Patient characteristics
N participants T0 187
N participants T1 174
N participants T2 171
N= 187 N (%)
Gender
• Male 111 (59)
• Female 75 (41)
Age mean (SD) 67 (13.9)
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table 1. Patient characteristics (continued)
Age groups
• < 60 46 (25)
• 60-69 53 (28)
• 70-79 59 (32)
• ≥ 80 29 (16)
First skin cancer?
• No 118 (63)
• Yes 49 (26)
• Unknown 20 (11)
Tumor site
• 1 162 (87)
• multiple 25 (13)
Tumor site
• scalp 14 (8)
• forehead 19 (10)
• nose 39 (21)
• eyelids 5 (3)
• cheeks 31 (17)
• lips 6 (3)
• other face 36 (19)
• neck 7 (4)
• trunk 14 (8)
• hands or feet 2 (1)
• extremity (not hands or feet) 14 (8)
Tumor type
• BCC 122 (65)
- superficial - 9 (5)
- nodular - 71 (38)
- infiltrative - 17 (9)
- morpheaform - 3 (2)
- micronodulair - 12 (6)
- infundibulocystic - 2 (1)
- unknown - 8 (4)
• SCC 65 (35)
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Overall scores for BaSQoL subscales were generally low, demonstrating a moderate 
impact on QoL. Patients with SCC tended to demonstrate higher levels of anxiety about 
their cancer than patients with BCC as measured by the Worries subscale (median score 
0.9 [IQR: 0.5-1.2] for BCC and median score 1.0 [IQR 0.5-1.4] for SCC, p=0.013). The SCI 
similarly measured moderate overall impact on quality of life and higher impact on the 
Emotional subscale for SCC patients. HADS scores were almost uniformly low, except for a 
few patients who indicated anxiety. Table 2 summarizes scores for the various instruments 
before treatment (T0).
table 1. Patient characteristics (continued)
Treatment
• Mohs surgery 170 (91)
• Conventional excision 17 (9)
Mohs rounds
• 1 88 (47)
• 2 51 (27)
• 3 14 (8)
• ≥ 4 16 (9)
table 2. HRQoL measurement T0
N = 187 BCC SCC p-value
BaSQoL (range 0-3)# N median score (IQR) N median score (IQR)
• Behaviour 122 1.0 (0.5-1.3) 63 0.5 (0-1.3) 0.281
• Diagnosis & Treatment 122 1.0 (0.3-1.3) 65 1.0 (0.3-1.3) 0.987
• Worries 120 0.9 (0.5-1.2) 61 1.0 (0.5-1.4) 0.013
• Appearance 118 0.3 (0-1.0) 64 0.3 (0-1.0) 0.344
• Other People 120 1.0 (0.5-1.5) 64 0.5 (0.5-1.5) 0.913
SCI (range 0-100)$
• Emotional 120 73.2 (57.1-82.1) 64 60.7 (39.3-81.3) 0.035
• Social 118 90.0 (80.0-95.0) 64 85.0 (71.3-98.8) 0.641
• Appearance 121 75.0 (50.0-92.0) 64 75.0 (50.0-100.0) 0.527
HADS (range 0-21)#
• Anxiety 122 4.0 (2.0-7.0) 65 4.0 (2.0-7.0) 0.659
• Depression 121 1.0 (0-3.5) 63 2.0 (0-4.0) 0.865
# Higher score indicates higher impact on HRQoL
$ Higher score indicates lower impact on HRQoL
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Each item on the BaSQoL was tested using eight performance features (Table 3). Poor 
performance is defined as suboptimal performance on 3 or more features. None of the 
BaSQoL items met criteria for poor performance. Five out of 16 BaSQoL items showed 
one suboptimal feature, and three out of the 16 BaSQoL items showed 2 suboptimal 
performance features. Internal consistency was good with Cronbach’s as ranging from 
0.63-0.80 for the different subscales (Behavior 0.80; Diagnosis & treatment 0.72; Worries 
0.74; Appearance 0.76; Other people 0.63).
The ICC between T1 and T2 was high (≥0.75) for nearly all subscales, indicating a stable 
response of the BaSQoL over time. Only the Worries subscale had moderate reliability (ICC 
0.64, 95% CI: 0.53 – 0.72) (Table 4).
BaSQoL subscales were strongly correlated with subscales of the SCI, demonstrating 
convergent validity, but were weakly correlated with HADS, indicating divergent validity 
(Table 5).
We observed a trend towards improvement in 3 subscales (behavior, diagnosis & treat-
ment and worries) and a trend towards deterioration in 2 subscales (appearance and 
other people) when comparing scores from before treatment (T0) to after treatment (T1). 
However, these changes did not reach statistical significance (Table 6).
table 3. Item performance of the BaSQoL questionnaire
N = 187 BaSQoL item number
Behavior Other 
People
Diagnosis & 
treatment
Worries Appearance Other 
People
Item performance features 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Item difficulty
Response distribution
Item-test correlation • • • •
Item-rest correlation
Item discriminant validity •
Item complexity •
Internal consistency • •
Stepwise regression • • •
• Indicates suboptimal performance in a given item feature. Definition of suboptimal performance in Supple-
mentary Table 1.
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table 4. Test-retest reliability BaSQoL subscales T1 and T2
N = 171
Subscale mean (SD) 
score test
mean (SD) 
score retest
Intraclass correlation 
coefficient*
95% CI p-value
Behavior 0.87 (0.62) 0.83 (0.66) 0.795 0.731 – 0.845 <0.001
Diagnosis & Treatment 0.86 (0.63) 0.84 (0.62) 0.801 0.740 – 0.849 <0.001
Worries 0.80 (0.60) 0.75 (0.59) 0.635 0.533 – 0.719 <0.001
Appearance 0.55 (0.66) 0.52 (0.69) 0.745 0.668 – 0.807 <0.001
Other People 0.94 (0.70) 0.93 (0.70) 0.754 0.680 – 0.813 <0.001
* Two-way mixed effect model
table 5. Convergent and divergent validity
N = 187 multitrait-multimethod correlation matrix using Spearman correlation coefficient
BaSQoL
Behavior Diagnosis & 
treatment
Worries Appearance Other People
Convergent validity: Skin Cancer Index
emotional -0.247* -0.532* -0.721* -0.369* -0.361*
95% CI -0.404/-0.091 -0.644/-0.402 -0.800/-0.623 -0.497/-0.231 -0.494/-0.213
Social -0.810 -0.424* -0.471* -0.562* -0.190*
95% CI -0.244/0.078 -0.550/-0.282 -0.586/-0.340 -0.668/-0.445 -0.327/-0.046
Appearance -0.201* -0.441* -0.288* -0.670* -0.134
95% CI -0.372/-0.059 -0.569/-0.309 -0.424/-0.131 -0.757/-0.573 -0.279/0.013
Divergent validity: Hospital Anxiety and Depression Scale
Anxiety 0.163* 0.402* 0.355* 0.394* 0.057
95% CI 0.020/0.315 0.260/0.525 0.205/0.492 0.247/0.518 -0.094/0.214
Depression 0.272* 0.235* 0.282* 0.376* -0.020
95% CI 0.119/0.409 0.079/0.369 0.134/0.413 0.239/0.504 -0.177/0.131
* Correlation is significant at the 0.042 level (2-tailed) (FDR corrected).
are hypothesized high correlations
table 6. BaSQoL subscale scores before and (4 weeks) after treatment
N = 174 mean (SD) mean 
difference*
95% CI of the 
difference
p-value
BaSQoL subscale t0 t1
• Behavior 0.91 (0.71) 0.87 (0.62) 0.04 -0.05 – 0.13 0.44
• Diagnosis & Treatment 0.94 (0.67) 0.87 (0.65) 0.07 -0.21 – 0.15 0.14
• Worries 0.88 (0.58) 0.82 (0.61) 0.06 -0.02 – 0.14 0.16
• Appearance 0.53 (0.59) 0.58 (0.67) -0.05 -0.15 – 0.05 0.34
• Other People 0.90 (0.71) 0.93 (0.71) -0.04 -0.13 – 0.06 0.48
* Paired samples T-test
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DISCUSSION
Health-related QoL has emerged as an essential outcome measure in dermatology. 
Therefore, disease-specific tools for measuring the impact of KC on QoL are needed. The 
BaSQoL questionnaire was developed following European Organisation for Research and 
Treatment of Cancer Quality of Life (EORTC QOL) group guidelines to comprehensively 
measure problems specific to patients with KC, such as fear of scars, coping mechanisms, 
worries about subsequent skin tumors, and the burden of sun protective behavior.
We have validated the English language translation of BaSQoL and demonstrated its utility 
in assessing an English-speaking American population. Using classical test theory, we have 
shown that BaSQoL performs well on all test features. Cronbach’s αs were reasonable to 
high and demonstrated good internal consistency.
As hypothesized, BaSQoL correlated very well to SCI in our study population. However, 
BaSQoL also has several advantages over existing quality of life tools for KC. BaSQoL mea-
sures sun protective behavioral changes due to skin cancer, measures worries about 
treatment, and measures the QoL impact reliably over time. Three different sections of 
the questionnaire measure QoL impact since diagnosis, between diagnosis and treat-
ment, and during the past week. This division of the questionnaire allows measurement 
of changing patient perceptions over time. In addition, BaSQoL addresses the impact of 
behavior change on patient QoL. The daily need for sun protection can be quite bother-
some to patients with a new diagnosis of skin cancer, but is also one of the most important 
interventions to prevent further keratinocyte carcinomas. Measuring the impact of sun 
protection on patient QoL may give us insight into best practices to encourage behavior 
change.
Health-related QoL scores measured by both BaSQoL and SCI in this study indicated a mod-
est impact compared to prior studies. [3,8] Our study population may have reported lower 
impact on QoL because the majority had a prior history of KC and may have been inured 
to the diagnosis. At least 63% had been treated for skin cancer previously and all of them 
were currently being treated at a tertiary referral center. Despite these low pre-treatment 
scores, the BaSQoL questionnaire was still able to detect a trend toward improvement in 
scores on 3 subscales (behavior, diagnosis & treatment and worries) and deterioration in 
2 subscales (appearance and other people) after treatment. This demonstrates that this 
questionnaire is sensitive to change and could be used to compare treatment modalities 
for KC. Although the changes detected in this study did not reach statistical significance, 
as mentioned before, our study population was drawn from a tertiary referral center, had 
more experience with skin cancer and thus may have been less impacted by this diagnosis, 
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all of which would bias scores towards a smaller impact. Another reason for the small dif-
ference in BaSQoL scores before and after treatment may be the short time span between 
T0 and T1. Surgical scars may still be healing at 4 weeks postoperatively. Longer follow up 
may be needed to detect differences in HRQoL as measured by BaSQoL.
Strengths of this study include the comparison of the BaSQoL to two other HRQoL instru-
ments, measurement of the BaSQoL at different time points, a sufficiently large sample of 
both BCC and SCC patients to test validity in both types of KC and excellent study comple-
tion with 91% of respondents completing the entire study. Limitations of this study include 
lack of a formal sample size calculation to measure sensitivity to change. As this is the first 
study measuring the BaSQoL before and after treatment, the anticipated difference was 
unknown before the start of the study and thus a formal calculation was not possible. 
The observed differences in the mean scores before and after treatment were very small, 
requiring at least more than 1,000 patients to show a statistical significant difference. As 
indicated before, larger differences may be observed within other patient populations or 
if longer periods of time are allowed between BaSQoL measurements.
In summary, the English language version of the BaSQoL has good face, content, and con-
struct validity given its ability to measure moderate quality of life decrement in patients 
with keratinocyte carcinomas, its broad range of content drawn from patients and subject 
experts, and its convergence with SCI, and divergence with HADS. This study validates 
BaSQoL as a QoL measure for BCC and SCC patients over time. BaSQoL may be a useful tool 
in future studies to compare treatment modalities, interventions for sun protective behav-
ior, or to identify patients in clinical practice with a substantial impact on their HRQoL who 
may benefit from additional clinical attention.
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Supplementary table 1. Definitions of item performance features used in classical test theory
Item Item performance 
feature
Definition
1 Item difficulty Proportion of missing scores among the 187 respondents. Item difficulty 
was considered high if 10% or more of scores were missing.
2 Response distribution The proportion of patients who responded to each item with the same 
response was determined. An item was described as having a poor 
distribution if > 70% of patients had chosen the same response.
3 Item–test correlation The Spearman’s correlation coefficients (r) of each item with its subscale 
were calculated. If the r of an item differed > 0.1 with the r of the other 
items in the subscale, it was considered suboptimal.
4 Item–rest correlation The Spearman’s correlation coefficients (r) of each item with the sum of 
the other items in that subscale were calculated. Suboptimal item–rest 
correlation was defined as r < 0.20
5 Item discriminant 
validity
We compared the item–rest correlation coefficients with the correlation 
coefficients of an item with the other subscales. If the former equalled or 
was smaller than the latter, an item was defined as having poor discriminant 
validity.
6 Item complexity We investigated the factor loadings in a factor analysis for each item. 
Suboptimal complexity was said to exist if the highest loading of an item 
was < 0.40 or if the difference between the loadings on different factors was 
< 0.10.
7 Internal consistency For each subscale, the Cronbach’s α was calculated. If α < 0.70, the internal 
consistency was considered suboptimal for each subscale’s item.
8 Stepwise regression For each subscale, a forward stepwise regression analysis was performed. 
If an item entered the model after 90% or more of the variance of that 
subscale was explained it was considered suboptimal.
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ABStRACt
This study aims to determine the satisfaction with information provision received by basal 
cell carcinoma (BCC) and squamous cell carcinoma (SCC) patients and associations with 
health-related quality of life (HRQoL). 1,173 patients from the Netherlands Cancer Regis-
try, received questionnaires on BCC/SCC-specific HRQoL (BaSQoL), cancer-specific HRQoL 
(EORTC QLQ-C30), information provision (EORTC QLQ-INFO25) and general satisfaction 
(EORTC INPATSAT-32). 721 (61%) patients participated. The HRQoL impact (BaSQoL) was 
higher among female and younger patients. One third (N=237) of all patients indicated 
to be dissatisfied with the information provision. Dissatisfaction with information provi-
sion was associated with younger age, facial tumour, not having a partner and multiple 
comorbidities. HRQoL was worse in patients dissatisfied with information provision (e.g. 
BaSQoL-worries mean score satisfied patients: 0.54 (95%CI:0.48–0.59 ), dissatisfied pa-
tients: 0.77 (95%CI:0.67–0.87 ), p=0.001). Dissatisfaction with provided information was 
associated with an impact on HRQoL. Possibly, HRQoL could be improved by improving the 
information provision.
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INtRODUCtION
Patient reported outcome measures (PROMs) and more specifically health-related quality 
of life (HRQoL) are increasingly being used in dermatology over the past decades. It is an 
essential and established outcome for clinical studies and in daily practice in inflamma-
tory skin diseases and is increasingly used in skin cancer.[1-3] Patients with keratinocytic 
carcinomas (KC), which include basal cell carcinoma (BCC) and squamous cell carcinoma 
(SCC), are likely to develop multiple lesions including actinic keratosis (AK) (so called ‘ac-
tinic neoplasia syndrome’).[4] Since the incidence of BCC and SCC continues to rise rapidly, 
it is important to identify patients with high disease burden in order to intervene ap-
propriately.[5-7] Recently, the basal and squamous cell carcinoma quality of life (BaSQoL) 
questionnaire was developed to measure disease specific HRQoL in BCC and SCC patients. 
[8]
An important factor associated with HRQoL is information provision. A systematic review 
in head and neck, breast, lung, gastro-intestinal, genitourinary and haematological cancer 
patients showed a positive association between information provision and HRQoL.[9] 
Information provision is considered as one of the most important aspects of supportive 
care, as an increase in knowledge about the disease and treatment leads to better illness 
perception, which could lead to a better HRQoL[10, 11]. However, this relation has not 
been described in BCC and SCC patients, and may differ from the aforementioned cancers, 
because the mortality is very low and treatment may have less impact. This study aims 
to assess current level of satisfaction with received information and the association with 
HRQoL in a large population-based sample of KC patients in the Netherlands. We hypoth-
esized that patients who were more satisfied with the received information reported a 
better HRQoL.
metHODS
Setting and participants
A cross-sectional study was performed among 1,173 patients, selected from the Southern 
region of the population-based Netherlands Cancer Registry (NCR), because during the 
study period, the NCR did not register all BCC and SCC nationwide yet. Patients were 
selected if they were diagnosed in one of the nine participating hospitals or clinics during 
the past twelve months before sending the questionnaire. Data was collected during the 
validation phase of the BaSQoL questionnaire.[8]
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Data collection
Participating patients completed a web-based questionnaire, or paper based on request. 
Patients were invited to participate through their dermatologist by a postal letter explain-
ing the study. When no reply was received, patients were sent a reminder several weeks 
later. Informed consent was obtained for the questionnaire and obtaining the clinical 
disease history data as registered by the NCR.
The questionnaire is part of the PROFILES (Patient Reported Outcomes Following Initial 
treatment and Long Term Evaluation of Survivorship) registry. PROFILES is a registry study-
ing physical and psychosocial impact of cancer and its treatment. It is linked directly to the 
data from the NCR[12].
Disease and patient characteristics
Socio-demographic data (age, education, occupation, partnership) was collected using 
standardized questionnaires. Disease specific data such as tumour type, location, treat-
ment and date of treatment were gathered from NCR.
Questionnaires
Information provision
Satisfaction with information provision was measured with the European Organisation 
for Research and Treatment of Cancer Quality of Life Questionnaire INFO25 (EORTC 
QLQ-INFO25) [13, 14]. This is a 25-item questionnaire to evaluate the provided informa-
tion received by cancer patients. The questionnaire consists of 4 subscales: information 
about the disease, medical tests, treatment, other services and additional single items. 
Responses are given in a 4-point Likert scale (‘not at all’, ‘a little’, ‘quite a bit’ and ‘very 
much’), except four items with a dichotomous yes or no response. All scales (excluding the 
satisfaction with information provision item) were converted to a 0-100 scale with higher 
scores meaning higher level of information received or higher wishes on information.
For this study, the 4-point Likert scale of the item ‘satisfaction with information provision’ 
was dichotomized into satisfied (‘quite a bit’ – ‘very much’) and dissatisfied ( ‘not at all’ – ‘a 
little’).
Health-related quality of life
Cancer-specific quality of life was measured by the EORTC QLQ-Core 30 (EORTC QLQ-C30), 
which is a 30 item questionnaire, divided in several scales: functional scales (physical, role, 
emotional, social and cognitive functioning), symptom scales (fatigue, pain and nausea/
vomiting) and single items concerning global health and quality of life, financial impact 
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and symptoms [15, 16]. All scales were converted to a 0-100 scale with higher scores 
meaning higher quality of life in the functional scales and more impact in the symptom 
scales.
The BaSQoL questionnaire was used to assess disease specific quality of life [8]. The BaSQoL 
is a 16 item questionnaire in which responses are given in a 4-point Likert scale (‘not at all’, 
‘a little’, ‘quite a bit’ and ‘very much’). The questionnaire is divided into 5 subscales (‘be-
havior’, ‘worries’, ‘appearance’, ‘diagnosis and treatment’ and ‘other people’). All subscale 
scores are converted to a 0-3 scale with higher scores implicating higher impact on HRQoL.
Patient satisfaction
The EORTC satisfaction with in-patient cancer care (INPATSAT-32) questionnaire addresses 
patient satisfaction with aspects of care, relevant to oncological disease [17]. It consists 
of several domains assessing doctors’ skills, nurses’ skills, information provision and avail-
ability, hospital personnel and the hospital generally, leading to 11 multi item scales and 
three single item scales. Responses are given in a 5-point Likert scale ranging from ‘poor’ 
to ‘excellent’. All scales were converted to a 0-100 scale with higher scores representing 
higher satisfaction with care. In the current study, the domain of INPATSAT-32 addressing 
nurses’ skills was not administered since the participants were predominantly outpatients 
and were generally not treated by nurses.
Comorbidity
Comorbidity was measured by the self-reported comorbidity questionnaire.[18]
Statistical analyses
Mean values of different scales were compared with independent samples T-tests between 
patients who were satisfied and dissatisfied with information. KC were studied collectively, 
but separate descriptive analyses for BCC and SCC were performed. Bar charts were cre-
ated to display the different values of the BaSQoL and EORTC QLQ-C30 subscales, stratified 
by satisfaction with information provision. Multivariable linear regression analysis was 
used to assess the association between the HRQoL as outcome measure (i.e., each sub-
scale of the BaSQoL) and satisfaction with information (i.e., satisfaction item of the EORTC 
QLQ-INFO25) as covariate. In order to take missing data into account in the regression 
analyses, we applied multiple imputation (25 imputations). In the imputation models we 
included all covariates and outcomes of the regression models. The model was adjusted 
for age at time of the questionnaire, time since diagnosis, sex, education, occupation, 
partnership, location of tumour, type of tumour and comorbidity. The selection of these 
variables was done a priori. The assumptions of multiple linear regression (no multicol-
linearity, normality of the residual values, homoscedascity) were met. A bar chart was 
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plotted to display the possible differences in satisfaction with information between the 
participating centres. As a secondary analysis, two multivariable logistic regression models 
were used to test if hospitals/clinics were independently associated with satisfaction with 
information provision or HRQoL, regardless of any of the aforementioned tumour and 
patient characteristics.
P-values <0.05 (two-sided) obtained from regression models were considered statistically 
significant. All other p-values were corrected for the false discovery rate proportion of 
true null hypothesis among significant results (Benjamini-Hochberg procedure) [19]. Cor-
rected p-values < 0.033 (two-sided) were considered statistically significant. All analyses 
were performed in IBM SPSS Statistics for Windows, Version 21.0 (Armonk, New York: IBM 
Corporation).
ReSULtS
721 of the 1,173 patients completed the questionnaire (response rate of 61% ). Of all 
respondents 85% had BCC and 15% had SCC. One third (N=237) indicated to be dissatisfied 
with the information provision as measured by the dichotomized item ‘satisfaction with 
information provision’ within the EORTC QLQ-INFO25 questionnaire. Dissatisfied patients 
were a few years older than satisfied patients (75 vs 71 years of age; table 1). Of all pa-
tients, 16% (N=116) indicated that they had wanted to receive more information about 
skin cancer in general, but also about causes, treatment and follow-up plan and how to 
recognize new lesions. This corresponds to 37% (84/225) of all dissatisfied patients and 
7% (28/416) of the satisfied patients. Three percent (N=24) wanted to have had received 
less information. The information received was considered helpful in 68% (N=417) of all 
patients. There was no difference in satisfaction about the information in the tumour type 
(BCC vs SCC) or BCC subtype (Table 1). Facial location of the tumour, not having a partner 
and having more comorbidities did show a statistical significant increase in dissatisfaction 
(Table 1). Patients who were dissatisfied with the information provision also scored sta-
tistically significantly lower on the general satisfaction with in patient care (as measured 
by the EORTC INPATSAT-32 questionnaire) and also on all other subscales of the EORTC 
INFO-25 (data not shown).
HRQoL, as measured by the BaSQoL and EORTC QLQ-C30 was statistically significantly 
lower among patients who were dissatisfied with information provision (figure 1a and 1b).
The distribution of satisfied versus dissatisfied with the information provision differed 
substantially between the 9 participating hospitals or clinics (Figure 2, Suppl. Table 1). 
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table 1. Basal cell carcinoma and squamous cell carcinoma patient characteristics according to satisfaction 
with information provision*
Dissatisfied patients#
N=237
Satisfied patient#
N=422
P-value
Age at time of survey in years, median (IQR) 75 (16) 71 (15) 0.015
Years since diagnosis , median (IQR) 4 (0.6) 4 (0.5) 0.363
Sex 0.148
• Male (%) 113 (33) 226 (67)
• Female (%) 124 (39) 196 (61)
Education 0.051
• Low 74 (41) 104 (58)
• Medium 142 (34) 279 (66)
• High 15 (30) 35 (70)
Current occupation 0.094
• (Self-) Employed 48 (30) 114 (70)
• Unemployed 168 (37) 289 (63)
Partnership 0.002
• Partner 163 (33) 339 (67)
• No partner 70 (47) 78 (53)
Tumour type 0.548
• BCC 203 (36) 358 (64)
• SCC 18 (32) 38 (68)
Location of tumour 0.004
• Face 197 (39) 311 (61)
• Other 40 (26) 111 (74)
Type BCC 0.633
• Multifocal superficial 14 (23) 48 (77)
• Infiltrating 51 (50) 51 (50)
• Nodular 124 (34) 238 (66)
• Other 14 (40) 21 (60)
Comorbidity < 0.001
• No 100 (28) 260 (72)
• 1 33 (40) 50 (60)
• ≥2 95 (49) 100 (51)
* Because of missing values numbers do not always add up to 721.
# Measured by the dichotomized item ‘satisfaction with information provision’ of the EORTC QLQ-INFO25 question-
naire.
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Figure 1a. BaSQoL subscale scores and satisfaction with information provision.
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Figure 1b. EORTC QLQ-C30 subscale scores and satisfaction with information provision.
Figure 1a and 1b. Mean BaSQoL And EORTC QLQ-C30 subscale scores and satisfaction with information provi-
sion.
Mean scores with standard error
* p value < 0.033 (FDR corrected)
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However, after adjustment for patient and tumour characteristics, participating centre was 
no longer associated with satisfaction with information provision (Suppl. Table 1). Also, 
participating centre was not statistically significantly associated with any BaSQoL subscale 
in a multivariable regression model (data not shown).
Satisfaction with information provision was associated with the behavior, diagnosis & 
treatment, worries and appearance subscales of the BaSQoL questionnaire with negative 
Beta’s (-0.3 to -0.1), indicating that satisfied patients had a 0.3 to 0.1 lower BaSQoL sub-
scale score, thus lower impact on HRQoL (table 2).
Other factors associated with worse HRQoL scores were younger age (all BaSQoL sub-
scales), recent time since diagnosis (on diagnosis & treatment, worries and appearance 
subscales of the BaSQoL questionnaire, indicating higher HRQoL impact if diagnosis and 
treatment was more recent) and being female (on diagnosis & treatment, worries and 
other people BaSQoL subscales). Facial location of the tumour was also associated with 
more HRQoL impact in the behavior, diagnosis and treatment and appearance subscales. 
Having a SCC led to a higher score than a BCC in the worries and other people subscales. 
No consistent effect on BaSQoL subscales was observed among different categories of 
patient’ education.
 Satisfied Dissatisfied
1 20 4
2 48 12
3 36 14
4 74 34
5 67 39
6 67 41
7 49 35
8 34 30
9 27 28
0%
10%
20%
30%
40%
50%
60%
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80%
90%
100%
1 2 3 4 5 6 7 8 9
Participating center 
Dissatisfied
Satisfied
Figure 2. Percentage of patients satisfied and dissatisfied with information provision per hospital / clinic. 
Ranked descending in percentage of satisfaction.
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DISCUSSION
In this cross-sectional population based study we demonstrated that patients who were 
dissatisfied with information provision had statistically significant higher impact on four of 
the five subscales of the BaSQoL and all of the EORTC QLQ-C30 subscales. There are two 
possible explanations for this correlation. First, patients dissatisfied with provided infor-
mation may not have sufficient knowledge about the disease and treatment and therefore 
have inadequate illness perception which causes more impact on HRQoL. Second, patients 
who reported a more negative impact of their disease on HRQoL are generally more dissat-
isfied with care, thus also with information provision. Since our study had a cross-sectional 
design, satisfaction with information and HRQoL were assessed at a single time point, 
so we cannot differentiate on which explanation is correct. Worse HRQoL on all BaSQoL 
subscales was found in younger patients. This is similar to the results of a pooled analysis 
studying the relation between age and HRQoL in cancer patients which showed that social 
functioning (as measured by the EORTC QLQ-C30) is better in older patients in comparison 
to younger cancer patients. [20]
In contrast to our hypothesis, being female did not show a significant association on the 
appearance subscale whilst it was associated with the diagnosis & treatment, worries and 
other people subscales. To improve the HRQoL impact in BCC and SCC patients, the BaSQoL 
could be used to identify patients with higher impact and provide supportive care accord-
ingly. Further research is necessary to identify which scores require additional attention.
This study also showed that one third of Dutch BCC and SCC patients were dissatisfied with 
the received information provision. These dissatisfied patients showed substantially lower 
scores on all subscales of provided information provision (EORTC INFO-25) in comparison 
to satisfied patients. Comparable results have been described earlier in patients with 
prostate cancer, multiple myeloma, lymphoma, endometrial cancer, colorectal cancer and 
thyroid cancer. In these studies the perceived receipt of disease-specific information was 
associated with better understanding of the disease and more personal and treatment 
control. [10, 11, 21] Especially in the dissatisfied with information provision group there 
is a wish for receiving more information. By taking into account the role of information 
provision in understanding, coping with the disease and choosing treatment, meeting the 
patients’ needs for more information is desirable. [9, 22] In this study factors associated 
with dissatisfaction with information provision were younger age, facial location of the 
tumour, not having a partner and having more comorbidities. Another study described 
lower income and education, female, unmarried status and type of cancer with good 
prognosis associated with patients’ perception of inadequate information provision.
[23] In comparison to our study the role of having no partner is similar. Lower education 
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level was not significant (p= 0.051) but did show a similar trend. No difference was seen 
between SCC and BCC.
We observed a large difference in how patients scored their satisfaction with information 
provision per hospital or clinic. These differences can partially be explained by the patient 
and tumour characteristics. But there is still room for improvement. These demonstrated 
differences underline the need for optimizing and standardizing the way to inform patients 
about their KC and possibly other diseases. The Dutch Society for Dermatology and Ven-
erology has developed several disease specific patient leaflets with general information 
about the disease and treatment. The results of our study suggest that the BCC and SCC 
information leaflets of the Dutch Society for Dermatology and Venerology (NVDV) are not 
fully satisfactory to all patients, that the leaflet may not always have been provided to the 
patient upon diagnosing BCC or SCC, or that certain subgroups of KC patients may require 
more detailed information (e.g., patients with facial tumours). Unfortunately, no specific 
questions about the general patient leaflet were included in our questionnaire. A recent 
discrete choice experiment (DCE), regarding patient preferences among patients with BCC 
in the Netherlands, indicated that patients prefer personalized information, rather than 
general information. [24]
Strengths & Limitations
Strengths of this study include, that it was a population-based disease-specific HRQoL as-
sessment of BCC and SCC patients, a validated questionnaire was used and a large sample 
was included. Therefore, the results can be generalized to the general population with 
BCC and SCC. A limitation of this study was the cross-sectional design and thus satisfaction 
with information and HRQoL were assessed at a single time point, therefore we cannot dif-
ferentiate if dissatisfaction with information provision leads to more HRQoL impact or vice 
versa. In addition, the time since diagnosis is different for patients within our sample and 
it would be informative to follow the BaSQoL scores at several time points after diagnosis 
within the same patient. For example, the scarring shortly after (surgical) treatment is 
more present so the appearance subscale score could decrease over time. The behaviour 
subscale score on the other hand could fluctuate over time with the changing of the 
weather and therefor the necessity to protect the skin against sunlight.
CONCLUSION
There is room for improvement in providing satisfactory information to BCC and SCC pa-
tients, especially in younger patients, patients with a facial location of the tumour, those 
who do not have a partner and have more comorbidities. Dissatisfaction with provided 
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information is associated with an impact on HRQoL which may be improved by improv-
ing the satisfaction in information provision. In addition to satisfaction with information, 
females and younger patients experienced a higher impact on several subscales of the 
BaSQoL. Possibly, these subgroups may require more supportive care, but further research 
is necessary to identify these patients based on their BaSQoL scores.
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Supplementary table 1. Satisfaction with information across participating centres.
Satisfied Dissatisfied Univariable multivariable *
N N OR (95%CI) p-value OR (95%CI) p-value
Participating centre
A 74 34 Ref. Ref.
B 48 12 1.84 (0.87 – 3.90) 0.11 2.02 (0.93 – 4.40) 0.08
C 36 14 1.18 (0.56 – 2.47) 0.66 1.39 (0.64 – 3.05) 0.41
D 20 4 2.30 (0.73 – 7.24) 0.16 1.89 (0.58 – 6.16) 0.29
E 34 30 0.52 (0.28 – 0.99) 0.05 0.53 (0.27 – 1.04) 0.07
F 49 35 0.64 (0.36 -1.17) 0.15 0.70 (0.37 – 1.32) 0.27
G 67 41 0.75 (0.43 – 1.32) 0.32 0.81 (0.45 – 1.74) 0.49
H 67 39 0.79 (0.45 – 1.39) 0.41 0.89 (0.49 – 1.62) 0.69
I 27 28 0.44 (0.23 – 0.86) 0.02 0.49 (0.24 – 1.00) 0.05
* The multivariable model was adjusted for HRQoL (Global subscale of the EORTC QLQ-C30) age at time of the ques-
tionnaire, time since diagnosis, sex, education, occupation, partnership, location of tumour, type of tumour and 
comorbidity
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ABStRACt
Background
Little is known about the impact of keratinocyte cancer (KC) and its treatment on health-
related quality of life (HRQoL). The aims of the present study were to [1] evaluate HRQoL 
among patients with KC in a population-based setting and compare this with an age- and 
sex-matched norm population, and [2] compare HRQoL, satisfaction with care and cos-
metic results for patients who underwent conventional excision, Mohs’ micrographic 
surgery, or radiotherapy.
methods
A random sample of 347 patients diagnosed with cutaneous basal cell (BCC) or squamous 
cell carcinoma (SCC) in the head and neck area between January 1, 2010 and December 
31, 2014 were selected from the Netherlands Cancer Registry (NCR) and were invited to 
complete a questionnaire on HRQoL, satisfaction with care, and cosmetic results. Data 
were collected within Patient-Reported Outcomes Following Initial Treatment and Long-
term Evaluation of Survivorship (PROFILES). Outcomes were compared to an age- and 
sex-matched normative population.
Results
Two hundred fifteen patients with KC returned a completed questionnaire (62% response). 
Patients with KC reported better global quality of life (79.6 versus 73.3; p<0.01) and less 
pain (p<0.01) compared to the norm population. No statistically significant differences in 
HRQoL, satisfaction with care, and cosmetic results were found between patients with KC 
who underwent conventional excision, Mohs’ micrographic surgery, or radiotherapy.
Conclusion
The impact of KC and its treatment seems relatively low and more positive than negative 
as patients reported better HRQoL compared to an age- and sex-matched norm popula-
tion probably due to adaptation. No statistically significant differences between treatment 
types were found concerning HRQoL, patients satisfaction and cosmetic results. This infor-
mation could be used by healthcare professionals involved in KC care to improve patients’ 
knowledge about different aspects of disease as patient’s preference is an important 
factor for treatment choice.
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INtRODUCtION
Keratinocyte cancer (KC) is the most common cancer in the Western world [1, 2]. Basal 
cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) account for respectively 80% 
and 20% of cases of KC [2-4]. These cancers are called KC because they share lineage 
with keratinocytes and histologically resemble epidermal keratinocytes [3]. Keratinocytes 
are vulnerable to damage from sun exposure and therefore KCs usually develop on sun-
exposed areas, especially the head and neck [5-8]. BCCs are slow-growing cancers that are 
nearly always asymptomatic, while SCCs may grow faster and may induce tenderness or 
pain, but are also mostly asymptomatic [3]. However, SCCs are more aggressive cancers 
with tendency to metastasis, especially the larger ones located on lips and ears [9].
KC is typically treated with surgical excision. However, less invasive options exist, such 
as radiotherapy, cryotherapy or topical therapy [3, 4, 10]. Choice of treatment depends 
on various factors, both clinical and personal. Important clinical factors are aggressive-
ness of the cancer, size and localization of the lesion, and especially for BCC, histological 
subtype [4, 11]. In addition, elderly patients and those with comorbid conditions are less 
suitable for surgical excision and are more likely to receive a less invasive treatment op-
tion. Furthermore, cosmetic aspects and patients’ preferences may also have impact on 
the choice of treatment, since treatment of KC can cause substantial facial cosmetic and 
functional disturbances [11]. Previous research showed that most prevalent concerns of 
patients with KC include worries about tumor recurrence, as well as the potential size and 
conspicuousness of the scar [12].
Patient-reported outcomes and health-related quality of life (HRQoL) are increasingly 
important outcomes in daily patient care [8, 13, 14]. HRQoL refers to an individual’s physi-
cal, psychological and social well-being, which may be affected by disease and treatment 
[15]. Since patients with KC are likely to develop multiple cancers during lifetime, KC and 
its treatment may be associated with impaired health-related quality of life (HRQoL) [16]. 
Despite the high incidence rates of KC and the importance of incorporating patient values 
into evidence-based medicine, little is known about the impact of specific treatment 
options for KC on HRQoL [13, 17]. In addition, the attention for perspectives of patients 
with KC is increasing over the past two decades, since previous research focused mainly 
on patients with melanoma [14, 18]. Satisfaction with care is also a part of the patient-
reported outcomes and more applicable to diseases with multiple treatment options, such 
as KC [19]. As patients with KC strongly expressed the need for a shared decision making 
process [20, 21], in which they are actively engaged and value detailed information regard-
ing their disease and treatment options, healthcare professionals that are working with 
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patients with KC need to understand their psychosocial concerns and needs in order to 
offer appropriate care services [22].
The aims of the present study were to [1] evaluate HRQoL among patients with KC in 
a population-based setting and compare this with an age- end sex-matched normative 
population, and [2] compare HRQoL, satisfaction with care and cosmetic results between 
patients who underwent conventional excision, Mohs’ micrographic surgery, or radio-
therapy.
metHODS
Setting and population
A cross-sectional cohort study was performed among patients with KC registered within 
the Netherlands Cancer Registry (NCR). Data from the NCR Eindhoven area were used to 
select a random sample of patients who were diagnosed with KC. The NCR Eindhoven area 
comprises an area with 2.4 million inhabitants (almost 15% of the Dutch population) in the 
South-Eastern part of the Netherlands. Patients diagnosed with at least one BCC or SCC in 
the head and neck area between January 1, 2010 and December 31, 2014 were eligible for 
participation. Patients with unverifiable addresses, with cognitive impairment, who died 
prior to the start of the study or were terminally ill and those with in situ lesions or who 
were already included in another study were excluded.
The NCR Eindhoven area is one of the few cancer registries that records data on BCC. 
The available data in the Netherlands Cancer Registry (NCR) does not include data on 
treatment – only histological diagnosis of first BCC [23]. If there is no histological infor-
mation concerning BCC (neither biopsy nor excision), patients are not registered in the 
NCR. This may especially be the case for patients who received radiotherapy, as not all 
carcinomas are histologically confirmed. We have opted for an oversampling of patients 
who received radiotherapy as primary treatment to enable a better comparison between 
treatment groups. Thus, we invited all eligible patients who received radiotherapy from 
two radiotherapy institutions.
Study measures
The Dutch-validated version of the European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) was used to assess generic 
HRQoL [24]. Answer categories range from one (not at all) to four (very much). After linear 
transformation, all scales and single items measures range in score from 0 to 100. A higher 
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score on functioning scores implies better health-related quality of life, whereas higher 
symptom scores refer to more symptoms [24].
The 16-item Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) questionnaire 
was used to capture impact of KC on HRQoL [14]. It assesses the relevant dimensions of 
HRQoL in patients with BCC and those with SCC. The individual items are scored from 0 to 
3, where 0 represents no impact and 3 very high impact. The mean score per subscale was 
calculated. A minimum of 50% of the questions within the subscale has to be answered in 
order to calculate the subscale score. No total score was calculated.
The Dutch version of the European Organization for Research and Treatment of Cancer 
In-Patient Satisfaction with care Questionnaire (EORTC IN-PATSAT32) was used to assess 
patient satisfaction [25]. Items were assigned a score from one (poor) to five (excellent). 
After linear transformation, all scales and single items measures range in score from 0 
to 100. Higher scale scores represent better satisfaction with care. Since the EORTC IN-
PATSAT32 was designed for in-patients, items about nurses and information provision at 
hospitalization and discharge were excluded from our questionnaire.
One single item was used to assess the cosmetic results of the treatment. This item was 
assigned a score from 1 to 10. A higher score reflects a higher level of satisfaction with the 
cosmetic result.
Comorbidity was categorized according to the adapted Self-administered Comorbidity 
Questionnaire (SCQ) [26]. Patients were asked to identify comorbid conditions present in 
the past 12 months. Positive responses were summed to obtain a total score (range 0-13).
Sociodemographic characteristics and clinical information were available from the NCR 
that routinely collects data on patients’ age and sex, date of diagnosis, cancer type, and 
treatment. As for BCCs only the first histologically confirmed carcinoma is registered, 
from the eligible BCC patients additional data on treatment, tumor size and morphology 
was manually collected by reviewing the patient records. Information on marital status, 
educational level, and employment status were assessed in the questionnaire.
Data collection
Data were collected within Patient-Reported Outcomes Following Initial Treatment and 
Long-term Evaluation of Survivorship (PROFILES). PROFILES is a registry for the study of 
the physical and psychosocial impact of cancer and its treatment from a dynamic, growing 
population-based cohort of both short- and long-term cancer survivors [27]. PROFILES is 
linked directly to clinical data from the NCR. In 2016, a survey was conducted among 345 
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individuals with BCC or SCC in the head and neck area. Eligible patients were informed 
about the study via a from their (former) dermatologist or radiotherapist. Patients were 
asked to complete and return the enclosed paper-and-pencil questionnaire. Patients were 
assured that refusing to participate in the study had no consequences for their follow-up 
care. If the questionnaire was not completed within 4 weeks, a reminder letter and a ques-
tionnaire was sent. More information about PROFILES and the data collection has been 
published previously [27]. (figure 1) All respondents have given written informed consent. 
This study was approved by the Medical Research Ethics Committees United (M15-0341).
Normative population
The normative population was selected from a reference cohort of 2,040 individuals 
from the general Dutch population (CentER panel). This cohort is representative for the 
Dutch population [28]. The set of questionnaires completed by this normative population 
in November 2011 included the EORTC QLQ-C30, SCQ, and data on sociodemographics. 
From this normative population, an age- and sex-matched selection was made to compare 
HRQoL with patients with KC. For matching, ten strata were formed using sex and age 
Figure 1. Flowchart of data collection process. 
 
 
A random sample of 400 patients with 
BCC or SCC in the head and neck area 
from the participating hospitals were 
selected from the Netherlands Cancer 
Registry (NCR) 
Specialists received a list with patients to 
assess eligibility 
Exclusion of 53 patients on advice of the specialists: 
- deceased prior to start of the study 
- cognitive impairment (e.g., dementia) 
- terminally ill 
- in situ lesions 
- participation in another quality of life study 
347 patients were invited to complete a 
questionnaire on HRQoL, satisfaction 
with care, and cosmetic results 
215 patients completed the 
questionnaire (62%) 
Outcomes were compared to an age- and 
sex-matched norm-population 
Figure 1. Flowchart of data collection process
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(five categories). Within each stratum a maximum number of persons from the reference 
were randomly matched according to the strata frequency distribution of the patients. 
This resulted in 277 matched cancer-free individuals for the 215 KC patients.
Statistical analyses
Differences in sociodemographic and clinical characteristics between patients with KC 
and an age- and sex-matched normative population were assessed with a Chi-square for 
categorical variables and t-tests for continuous variables. Differences in sociodemographic 
and clinical characteristics between patients with KC according to treatment regime were 
also assessed with a Chi-square and t-tests, where appropriate.
Mean EORTC QLQ-C30 scores from the patients with KC were compared with the mean 
scores of an age- and sex-matched normative population using independent sample t-tests. 
To compare HRQoL scores between patients with one versus multiple skin cancer, we used 
analyses of covariance (ANCOVA) adjusting for age. To compare mean scores between 
patients with KC who underwent conventional excision, Mohs’ micrographic surgery, or 
radiotherapy on QLQ-C30 scales, symptoms, BaSQoL scales, IN-PATSAT32 scales, general 
satisfaction with care, and cosmetic results, we used analyses of covariance (ANCOVA) 
adjusting for age. Age was calculated at the time of administering the questionnaire.
All statistical analyses were performed using SAS (version 9.4 for Windows; SAS Institute 
Inc., Cary, NC). P values of <0.05 were considered statistically significant. Clinically relevant 
differences were determined using the evidence-based guidelines for interpretation of the 
EORTC QLQ-C30 between groups [29].
ReSULtS
Patient characteristics
Two hundred fifteen patients with KC returned a completed questionnaire (62% response). 
Respondents were younger compared to non-respondents (p<0.001) and had a more 
recent diagnosis of KC (p=0.004; Table 1). No differences between responding and non-
responding patients were found according to type of cancer or localization.
The mean age at completion of the questionnaire was 71.3 years with a mean time since 
diagnosis of 3.3 years. Most patients were diagnosed with BCC (81%) and almost half 
of all patients reported they have had more than one skin cancer. Medium educational 
level was most common (60%). Comorbid conditions were reported by 75% of patients. 
In the normative population, mean age at questionnaire completion was 69.3 years with 
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a comorbidity percentage of 70%. In our sample, 49% of patients with KC underwent 
conventional excision, 26% radiotherapy and Mohs’ micrographic surgery was received 
by 9% of patients with KC. The remaining patients received a variety of treatments, such 
as photodynamic therapy, cryotherapy or topical chemotherapy. This group, however, is 
too small to be further outlined. Patients who received radiotherapy were significantly 
older (75.9 years) than patients with KC who underwent conventional excision or Mohs’ 
micrographic surgery (68.2 and 67.4 years, respectively; p<0.001). In addition, patients 
who received radiotherapy had more often cancer located on the nose (60%) compared to 
patients treated with conventional excision or Mohs’ micrographic surgery (25 and 32%, 
respectively; p<0.001) (Table 2).
table 1. Sociodemographic and clinical characteristics of responding and non-responding patients with kera-
tinocyte cancer (KC), and an age- and sex-matched normative population
Respondents Non-respondents Norm population
N=215 N=130 N=255
N (%) N (%) N (%)
Sex
Male 116 (54) 66 (51) 137 (54)
Female 99 (46) 64 (49) 118 (46)
Age at time of survey: mean (SD) 71.3 (11.9) 76.6 (14.1)* 69.3 (12.8)
<50 14 (7) 6 (5) 16 (6)
50-59 24 (11) 13 (10) 27 (11)
60-69 38 (18) 13 (10) 45 (18)
70-79 89 (41) 31 (24) 105 (41)
80+ 50 (23) 67 (52) 62 (24)
Years since diagnosis: mean (SD) 3.3 (1.4) 3.7 (1.5)*
Educational level#
Low 34 (17) 95 (37)*
Medium 120 (60) 62 (24)*
High 47 (23) 98 (38)*
Partner
Yes 66 (31) 83 (33)
No 149 (69) 172 (67)
Self-reported comorbidities: mean (SD) 1.5 (1.5) 1.4 (1.3)
Most frequent comorbid conditions
Hypertension 64 (32) 92 (36)
Arthritis 65 (32) 81 (32)
* Significantly different from respondents (p<0.05); # Educational levels were low = none/primary school; medium 
= lower general secondary education/vocational training; or high = pre-university education/ high level vocational 
training/university.
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table 2. Sociodemographic and clinical characteristics of questionnaire respondents who were treated with 
radiotherapy (n=55), conventional excision (n=106), and Mohs micrographic surgery (n=19).
Conventional 
excision
mohs’ 
micrographic 
surgery
Radiotherapy
p-value
N=106 N=19 N=55
N(%) N(%) N(%)
Sex 0.34
Male 54 (51) 8 (42) 33 (60)
Female 52 (49) 11 (58) 22 (40)
Age at time of survey: mean (SD) 68.2 (11.9) 67.4 (13.2) 75.9 (9.7)
<50 9 (8) 4 (21) 0 (0) ≤0.001
50-59 17 (16) 1 (5) 4 (7)
60-69 24 (23) 4 (21) 6 (11)
70-79 39 (37) 6 (32) 28 (51)
80+ 17 (16) 4 (21) 17 (31)
Education level1 0.37
Low 14 (14) 1 (5) 10 (20)
Medium 59 (60) 11 (58) 32 (63)
High 26 (26) 7 (37) 9 (18)
Partner (yes) 77 (73) 17 (89) 36 (65) 0.13
Type of cancer 0.30
BCC 86 (81) 18 (95) 48 (87)
SCC 15 (14) 1 (5) 7 (12)
Unknown 5 (5) 0 (0) (0)
Number of skin cancers 0.04
One skin cancer 44 (42) 9 (50) 33 (63)
More than one skin cancer 60 (58) 9 (50) 19 (37)
Localization ≤0.001
Forehead 16 (15) 1 (5) 4 (7)
Scalp 23 (22) 1 (5) 3 (5)
Nose 26 (25) 6 (32) 33 (60)
Ear 9 (8) 3 (16) 6 (11)
Lip 3 (3) 3 (16) 2 (4)
Other parts of head and neck 29 (28) 5 (26) 7 (13)
Number of comorbidities: mean (SD) 1.2 (1.2) 1.4 (1.7) 1.6 (1.2) 0.22
Most frequent comorbid conditions
Hypertension 21 (21) 8 (42) 20 (41) 0.02
Arthritis 26 (26) 6 (32) 16 (33) 0.67
1 Education levels were low = none/primary school; medium = lower general secondary education/ vocational train-
ing; or high = pre-university education/ high level vocational training/university.
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Comparison between patients with multiple skin cancers and one skin cancer
Patients with multiple skin cancers were less satisfied with the cosmetic results compared 
to patients with one skin cancer (8.3 versus 7.7, p<0.01) (Figure 2), and were more con-
cerned about their appearance (0.18 versus 0.32, p=0.04). No significant differences were 
found on HRQoL (as measured with the EORTC QLQ-C30 and BaSQoL) between patients 
with one or multiple skin cancers (all p>0.05). No differences between patients with infil-
trative and non-infiltrative BCC were found in HRQoL scores, general satisfaction with care 
and cosmetic results (all p>0.05).
Comparison between patients with KC and an age- and sex-matched normative 
population
No statistically significant differences were observed between patients with KC and an 
age- and sex-matched norm population on physical, emotional, cognitive, social, and role 
functioning (EORTC QLQ-C30) (all p>0.05). However, patients with KC reported statistically 
significant better scores on global quality of life (79.6 versus 73.3; p<0.01) and they reported 
less pain (p<0.01) compared to a normative population (Figure 3a and 3b). These repre-
sented small clinically important differences. Other symptoms were comparable (p>0.05).
* p < 0.001
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One skin cancer (N=99) Multiple skin cancers (N=108)
*
Figure 2. Differences in cosmetic results between patients who have had one skin cancer (N=99) and patients 
who have had multiple skin cancers (N=108).
* P < 0.001
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Comparison between treatment groups
No differences in global quality of life, functioning scores (both EORTC QLQ-C30) or 
BaSQoL mean scores were found between patients treated with conventional excision, 
Mohs’ micrographic surgery and radiotherapy (all p>0.05, Figure 4a and 4b, Table 3).
Patients with KC who underwent radiotherapy were more satisfied with the cosmetic 
results than patients who underwent conventional excision or Mohs’ micrographic surgery 
(8.5 versus 7.8 and 7.9, respectively), but this difference was not statistically significant 
(p=0.06) nor clinically relevant. Patients who underwent radiotherapy reported better 
scores for hospital comfort/cleanness (72.1 versus 62.9, p=0.03) compared to patients 
treated with conventional excision. No other statistically significant differences were found 
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Figure 3a and 3b. Differences on EORTC QLQ-C30 mean functioning and global quality of life (a) and symptom 
scores (b) between patients with KC (N=215) and an age- and sex-matched normative population (N=255).
* p < 0.05 and small clinically important difference; A higher score on functioning scores implies a better health-relat-
ed quality of life, whereas a higher score on symptom scores refers to more symptoms. EORTC QLQ-C30 = European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30.
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between treatment groups. In all treatment groups, approximately half of the patients 
rated their general satisfaction with care as “very good” or “excellent”.
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Figure 4a and 4b. Differences on EORTC QLQ-C30 mean functioning and global quality of life (a) and symptom 
scores (b) between patients with KC who underwent conventional excision (N=106), Mohs’ micrographic sur-
gery (N=19), or radiotherapy (N=55).
A higher score on functioning scores implies a better health-related quality of life, whereas a higher score on symp-
tom scores refers to more symptoms. EORTC QLQ-C30 = European Organisation for Research and Treatment of Can-
cer Quality of Life Questionnaire Core 30.
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DISCUSSION
In this study, patients with KC reported better global quality of life and less pain com-
pared to an age- and sex-matched norm population. Similar results have previously been 
observed among patients with other types of cancer [30, 31], and among patients with 
melanoma [32]. A possible explanation is that patients score better because they adapt 
the new situation of having a skin cancer diagnosis, assessing their quality of life better 
than before the diagnosis, the so-called response shift [33].
table 3. Differences between patients treated with radiotherapy, conventional excision, and Mohs’ micro-
graphic surgery on mean EORTC IN-PATSAT32 scores and cosmetic result, adjusted for age.
 
 
Conventional 
excision
mohs’ micrographic 
surgery
Radiotherapy
p-value
N=106 N=19 N=55
Mean (SD) Mean (SD) Mean (SD)
BaSQoL (0-3)1
Behaviour 0.7 (0.7) 0.5 (0.5) 0.6 (0.7) 0.27
Diagnosis and treatment 0.9 (0.7) 1.0 (1.0) 1.1 (0.7) 0.39
Worries 0.7 (0.6) 0.7 (0.7) 0.9 (0.7) 0.44
Appearance 0.3 (0.5) 0.2 (0.5) 0.3 (0.4) 0.19
Other people 0.7 (0.7) 0.5 (0.6) 0.6 (0.7) 0.28
eORtC IN-PAtSAt32 (0-100)2
Doctors’ technical skills 65.4 (19.4) 68.9 (14.4) 66.6 (22.0) 0.77
Doctors’ interpersonal skills 58.2 (22.2) 67.1 (20.1) 63.0 (22.9) 0.19
Doctors’ information provision 64.5 (21.4) 71.9 (22.1) 69.3 (22.0) 0.24
Doctors’ availability 55.5 (24.3) 65.3 (19.0) 59.7 (25.2) 0.23
Other hospital staff interpersonal skills 
and information provision
66.9 (20.0) 64.5 (20.9) 73.6 (22.9) 0.12
Exchange of information between 
caregivers
56.1 (21.2) 53.9 (28.0) 58.8 (21.7) 0.66
Waiting time 61.4 (18.2) 54.6 (25.4) 64.9 (22.6) 0.17
Hospital access 60.5 (18.3) 64.5 (21.4) 66.6 (23.2) 0.20
Hospital comfort/cleanness 62.9 (19.2) 68.4 (18.3) 72.1 (23.6) 0.03
General satisfaction 64.4 (19.6) 68.1 (18.8) 68.8 (21.6) 0.43
Cosmetic results (0-10)3
Cosmetic results 7.9 (1.5) 7.8 (1.5) 8.5 (1.1) 0.06
Results in bold are statistically significant different. 1 A higher score implies more impact of the disease; 2 A higher 
score implies more satisfaction; 3 A higher score represents more satisfaction with the cosmetic result.
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Although different treatment options may lead to different HRQoL scores, we found simi-
lar scores on functioning and global quality of life among patients with KC who underwent 
conventional excision, Mohs’ micrographic surgery or radiotherapy. This is in line with 
research among patients with KC that showed similar HRQoL after excision and Mohs’ 
micrographic surgery [13]. It was expected that patients who underwent radiotherapy 
might experience their treatment as more severe, as they need to visit the hospital several 
days in a row for therapy. Irradiation can also result in complaints about ‘burning’ of the 
skin [34, 35]. We found that patients who underwent radiotherapy were more satisfied 
with the cosmetic results, however this was not statistically relevant. The mean time since 
diagnosis was more than 3 years, so it might be that complaints about burning of the skin 
are not relevant anymore after few years, while scars as a result of conventional excision 
or Mohs’ micrographic surgery might remain more visible, especially when patients have 
had multiple skin cancers. It is likely that adverse aspects of different treatment options 
are of greater impact on HRQoL when patients are closer to diagnosis [13]. In this study, 
we included only patients with KC who have been diagnosed at least one year before 
questionnaire completion. More complaints might be expected when patients are closer 
to treatment.
Patients who had multiple skin cancers reported lower cosmetic results and more concerns 
about their appearance compared to patients who had only one skin cancer. Previous 
research showed that potential disfigurement and scarring is a concern for many patients 
[11, 12, 36], especially multiple scars from multiple skin cancers.
Approximately half of the patients with KC rated their general satisfaction with care as 
“very good” or “excellent”. High cure rates of both excision and radiotherapy (>90%) might 
therefore be an explanation for high satisfaction scores [37].
The current study has some limitations, such as the small sample size, which may limit sta-
tistical significance of our findings. The sample size is especially small for patients treated 
with Mohs’ micrographic surgery. At the time patients included in this study were treated, 
the benefits of Mohs’ micrographic surgery in the treatment of BCC and SCC had not yet 
been sufficiently demonstrated [38, 39]. Therefore, Mohs’ micrographic surgery was not 
a standard of treatment for KC yet and as a result of which it was used less frequently. 
The availability of Mohs’ micrographic surgery in the NCR Eindhoven area has increased 
since 2014. The study should be replicated with a larger sample of KC patients to get 
more conclusive results. In addition, we did not have detailed information on radiotherapy 
schedules of KC. Therefore, we are not aware whether the frequency of radiotherapy ap-
pointments has impact on HRQoL and satisfaction with care. Furthermore, we did not 
have detailed information of non-responding patients. Previous research reported that 
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patients not participating in observational PRO research may systematically have lower 
HRQoL scores compared to participants [40]. Therefore, observed outcomes might repre-
sent the healthier patient with better outcomes.
In conclusion, despite the cross-sectional design of this study, this population-based study 
give an overview of the HRQoL that patients with KC experience after their disease and 
treatment. The impact of KC and its treatment seems relatively low and more positive than 
negative as patients reported better HRQoL compared to an age- and sex-matched norm 
population probably due to adaptation. No statistically significant differences between 
treatment types were found concerning HRQoL, patients satisfaction and cosmetic results. 
This information could be used by healthcare professionals involved in KC care to improve 
patients’ knowledge about different aspects of disease as patient’s preference is an impor-
tant factor for treatment choice.
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General discussion
The aims of this thesis were to develop and validate a disease-specific health-related qual-
ity of life (HRQoL) questionnaire and assess HRQoL and patient perception on disease, 
treatment and provided information in keratinocyte carcinoma (KC) patients. This final 
chapter reflects on the main findings and limitations, and concludes with a discussion on 
future perspectives.
Health
In order to discuss HRQoL, it is important to discuss the definition of health. The definition 
used until 2011 was formulated by the World Health Organization (WHO) in 1948 and 
describes health as “a state of complete physical, mental and social well-being and not 
merely the absence of disease or infirmity.”[1] This definition has been criticized but was 
never adapted. In 2011, Hubert et al proposed a new definition; “health is the ability to 
adapt and self-manage”, which has been accepted since.[2]
(Health-Related) Quality of life
Since the introduction of ‘quality of life’ in medicine, it is being used increasingly as an 
outcome of care in studies. Unfortunately, there is no consensus on a definition for ‘quality 
of life’ and it may appear as health status, physical functioning, perceived health status, 
subjective health, health perceptions, symptoms, need satisfaction, individual cognition, 
functional disability, psychiatric disturbance, well-being and -quite often- several of these 
at the same time. In order to clarify these issues, the term ‘health-related quality of life’ 
was defined as the value of a life affected by illness and disease. It is a multidomain con-
cept representing the general perception of the effect of illness and treatment on physical, 
psychological, and social aspects of life. [3]
It has been stated that in reality it is impossible to separate effects due to health and 
other effects which are a consequence of changing patterns such as finance, friendship, 
occupation and ageing.[4-6] It does however add value to the patient’s perspective and 
the clinicians perspective in the evaluation of treatment outcomes. And aiming for the 
best possible physical and emotional state compatible with the medical condition has the 
best chance of achieving a high quality of life.[7] The European Organization for Research 
and Treatment of Cancer (EORTC) Quality Of Life Group uses the following definition: 
HRQoL covers the subjective perceptions of the positive and negative aspects of cancer 
patients’ symptoms, including physical, emotional, social, and cognitive functions and, im-
portantly, disease symptoms and side effects of treatment. [8] When incorporating HRQoL 
measurement into clinical practice, it is recommended to evaluate the usefulness of the 
questionnaires as experienced by the patient. [9] An example of HRQoL use in clinical 
practice is in patients with chronic idiopathic urticaria. The guideline of the Dutch Society 
of Dermatology recommends that measurement with a disease specific and a dermatol-
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ogy specific HRQoL instrument, and a specific minimal score, is necessary before starting 
omalizumab treatment. [10]
In oncology, the aforementioned EORTC Quality Of Life Group started to develop the 
EORTC quality of life core questionnaire (QLQ-C30) in 1986. The main goal was to develop 
an instrument suitable for standardized HRQoL measurement in international clinical trials 
in oncology. [11] In the following decades, the majority of clinical trials in oncology re-
ported HRQoL assessment, especially in systemic treatments for metastasized cancer with 
or without radiotherapy since there are substantial disease and treatment effects on the 
short and long term. The tendency to investigate HRQoL in cancer therefore was mainly in 
metastasized cancer. Non-metastasized cancer and KC were only studied sparsely during 
this period.
In dermato-oncology, specifically in KC patients, the first sparse attention for HRQoL was 
in the late 90’s, suggesting little to no HRQoL impact in BCC patients, measured with 
generic and dermatology specific HRQoL questionnaires. [12] This is most likely due to 
the often straightforward surgical treatment and lack of severe and lasting side effects 
of treatments. Measuring HRQoL with both a generic and a specific HRQoL instrument 
is preferable over only using a generic HRQoL instrument to assess impact and respon-
siveness.[13] Unfortunately, existing HRQoL questionnaires for KC were not suitable for 
use, because of methodological flaws, such as the use of multiple issues and questions 
combined in one item. They also failed to capture one of the most reported issues in skin 
cancer patients; the often required behavioral changes (and related psychological issues) 
to reduce sun exposure.[14] A previous study by Holterhues et al. showed that Dutch 
melanoma survivors reported a better quality of life than the general population, but 
nevertheless, reported substantial impact on ‘melanoma specific’ items suggesting that 
their diagnosis did affect their quality of life.[15] In this thesis we identified the HRQoL 
issues in KC patients (chapter 3) and tested the impact of these issues in population based 
samples (chapter 5 and 6). The identified issues have some overlap with issues in existing 
HRQoL questionnaires used in skin cancer patients, such as concerns about appearance 
and scarring, sun behavior and fear of cancer recurrence or spreading.[16-18] The BaSQoL 
questionnaire however also captures treatment and diagnosis related issues and issues 
related to long-term behavioral changes.
Another unique feature of the BaSQoL questionnaire is the use of different time-frames 
within the questionnaire. This was created since patients mentioned a distinct difference 
in behavior before and after the initial skin cancer diagnosis. The first part of the BaSQoL 
captures the impact of these changes. The second part of the questionnaire assesses the 
usually short period between diagnosis and treatment. This is a known stressful period for 
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patients with cancer with a high impact on the HRQoL and measurement helps to assess 
the patient’s experience of this period. Patients with high HRQoL impact may benefit from 
additional care, especially in case of first tumours. The final part of the BaSQoL is more 
classic in the way that it concerns the HRQoL impact of the skin cancer in the past week. 
By using this three time periods concept, the questionnaire addresses the several issues in 
the right context. The downside to this is that it requires more thought and therefore may 
be more difficult to complete.
The validation of the English version of the BaSQoL and the simultaneous assessment of 
the construct validity by comparison with the Skin Cancer Index, test-retest stability and 
responsiveness to change completed the validation of the newly created questionnaire 
(chapter 4).
The measurement of the HRQoL impact in KC patients in chapter 5 and 6 showed a higher 
impact in younger patients and patients who were dissatisfied with provided informa-
tion about the disease. Female patients had higher impact in some of the subscales, but 
surprisingly not on the appearance subscale. In comparison to an age- and sex-matched 
normative population, patients with KC reported statistically significant better scores on 
global quality of life as measured by the EORTC QLQ-C30 questionnaire. This is also seen 
in melanoma and may be explained by the so-called response shift; adaptation to the new 
situation of having a skin cancer diagnosis and better assessment of their QoL than before 
diagnosis.[19, 20] Patients with BCC even have a lower all-cause mortality in comparison 
to the general population. [21]
When comparing BaSQoL scores of patients who have had different treatments for their 
KC (conventional excision, Mohs’ micrographic surgery or radiotherapy), no differences 
were found. In general, the impact of KC and its treatment seems relatively low in differ-
ent treatment groups. These findings are similar to the findings of Chren et al. in 2007, 
comparing conventional excision, Mohs’ micrographic surgery and electrodessication and 
curettage. [22]
The use of the BaSQoL in KC still needs further investigation. Especially to determine the 
optimal timing of questionnaire administration and clinical implications of scores. The 
BaSQoL seems to be a useful tool to assess the impact of KC diagnosis in order to identify 
these patients at risk for major HRQoL impact.
A problem in the current way of measuring HRQoL in oncology is the extensive and lengthy 
course of the development of a questionnaire. The development of the BaSQoL, from 
phase 1 to the final acceptance of the manuscript took 5 years (Figure 1), similar to many 
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other HRQoL questionnaire developments in oncology. Especially in questionnaires for 
cancer addressing symptoms due to systemic therapy, by the time the questionnaire is 
ready for use, it is already outdated due to the rapid development and implementation 
of new cancer therapies. [23, 24] Another approach in this field, to monitor symptoms 
during systemic cancer treatment, is the Patient-Reported Outcomes Version of the Com-
mon Terminology Criteria for Adverse Events (PRO-CTCAE). It is a questionnaire which is 
customizable for use in cancer trials, measuring symptomatic adverse events. The specific 
items which are needed for a study can be selected from the item bank (which is a da-
tabase of previously studied and validated items).[25] In this way, a new questionnaire 
can be assembled rather quickly, fitted for the new therapy, without the time consuming 
process of developing a completely new questionnaire. Fortunately, symptoms are not 
much of an issue in KC or KC treatment options and are thus not included in the BaSQoL.
Patient Reported Outcomes
Patient Reported Outcomes (PROs) are outcomes about a disease, health or treatment 
directly from patients without interpretation. It includes HRQoL, but also other outcomes 
such as severity and frequency of symptoms, treatment satisfaction, functional status and 
well-being but in general, it reflects how patients feel.[26] It includes for example symptom 
checklists such as pain and itch, which are also being used in chronic idiopathic urticaria 
[10]. By collecting PRO’s, the caregivers are able to understand the impact of disease and 
treatment better and therefore able to intervene and thus optimize how patients feel. [27] 
In cancer, PRO monitoring has shown improvements in patient-care-provider communica-
tion. [28] It also helps to identify issues patients might not have raised and that clinicians 
would therefore assume were not of concern, on which tailored care can be provided. In 
oncology, the web-based self-management application “Oncokompas” is being integrated 
in routine cancer-care, monitoring health-related quality of life and support cancer sur-
vivors in finding and obtaining optimal supportive care. [29] It assesses a wide range of 
outcomes, covering the following domains: physical, psychological, social, healthy lifestyle 
and existential issues. Completing PROs might also make patients feel cared for, and there-
fore improving emotional functioning.[30] It was shown, that improved physician-patient 
communication resulted in better HRQoL and emotional functioning for a proportion of 
patients. [31] In research it can be used to identify the benefits and harms of treatments 
and interventions.[32] This all will improve outcomes and also patient-centeredness, as 
is demonstrated in a study using the PRO-CTCAE, even improving survival when using 
web-based symptom monitoring versus routine surveillance following treatment for lung 
cancer. [33]
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Figure 1. Timeline of the development of the BaSQoL questionnaire.
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By routinely monitoring PROs, care can be tailored to match the patients’ needs. [26, 28, 
34] By providing feedback about the PRO, patients have their own responsibility to discuss 
issues with their treating physician or their general practitioner.
Another use for PRO is to monitor the patient post-treatment. The time between the 
(surgical) treatment and the first follow-up visit may be used to proactively address and 
manage symptoms and following problems (e.g. complications, urgent care evaluations). 
[35]
Patient centered care
The National Academy of Medicine (formerly known as Institute of Medicine) formulated 
six dimensions of patient-centered care, which stated that care must be: 1) respectful to 
patients’ values, preferences, and expressed needs; 2) coordinated and integrated; 3) pro-
vide information, communication, and education; 4) ensure physical comfort; 5) provide 
emotional support – relieving fear and anxiety; and 6) involve family and friends.[36, 37] 
To measure these dimensions the use of PROs is needed. HRQoL measurement can help 
to identify needs and preferences, assess satisfaction on information and help to optimize 
physical and emotional needs. A recent qualitative study in BCC and SCC patients showed 
the wish for investing in the patient–physician relationship and personalizing the type and 
form of information and the follow-up schedules.[38] The BaSQoL can help to identify if 
there are any issues bothering the individual patient. The behavior subscale for example 
helps to evaluate if the patient can fit the often required behavioral changes after the first 
skin cancer diagnosis into his/her daily life whilst not interfering with patients’ values and 
preferences. The worries and also the diagnosis & treatment subscales address fear and 
anxiety. On the other hand is the BaSQoL useful for assessment on group level and these 
results may be used to compare individual scores to group scores.
Specifically in cancer care, a more holistic approach to the patient is desirable, also assess-
ing supportive care, encompassing clinical, ethical/existential and spiritual dimensions.
[39] To measure the needs of supportive care, questionnaires exist. [40, 41] Existing 
HRQoL questionnaires may even be used to identify a change in patients’ supportive care 
needs.[42] The BaSQoL may also be used for this purpose since it is specific enough to 
identify the patients with high impact of the diagnosis and treatment. In daily practice, 
we notice that additional (supportive) care is helpful in managing anxiety in patients. 
Detailed and personalized information provided by the doctor or the nurse helps to cope 
with the disease and manage it in daily life. Further research should assess how to use and 
interpret the BaSQoL for this purpose.
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Another way to center the patient in the care process is to empower them to own their 
PRO results. A current study in lymphoma patients evaluates the impact of providing 
patients PRO with feedback. [43] Results of a pilot study suggest that a high number of 
patients wished to receive PRO feedback and that they would find the comparison of their 
scores versus a disease specific reference cohort most valuable. [44] This current ongoing 
study will provide information about the usefulness of providing feedback to the patient 
on PRO. Whatever the outcomes of this study will be, providing individual PRO results 
to the patient can help to address the deviant outcomes or subscales with their treating 
physician. But with empowerment also comes responsibility for the patient creating a 
bilateral perspective on the concept of ‘shared decision making’.
Strengths and limitations of the studies in this thesis
The impact of KC on HRQoL seems to be limited in most patients, but the smaller propor-
tion of patients on which KC has a larger impact on HRQoL need to be identified in order 
to provide additional care. Since the total number of KC patients is high, even a small 
proportion of patients with high HRQoL impact means that a high absolute number of 
patients might  suffer.
The development of the BaSQoL questionnaire has been thorough in all aspects of the 
development in comparison to other skin cancer specific HRQoL questionnaires. The 
development phase was designed and executed mostly following EORTC questionnaire de-
velopment guidelines. The patient sample was population-based with a generous sample 
size and the analyses were not only the state of the art Item Response Theory analyses, 
but also included conventional classical test theory principles. The population based ap-
proach which we used in chapter 3, 5 and 6 helps to study a large group of patients over 
several hospitals and clinics. However, information about treatment was also based on 
patients’ self-report and therefore may be less accurate.
Interpretation of the BaSQoL subscale scores may be time-consuming in daily clinical 
practice since it concerns several subscales and a minimal clinically important difference 
or any other cut-off scores to help interpret the scores do not yet exist.
Development was done in one country and cross cultural difference may exist, but in the 
validation study of the English version of the BaSQoL in chapter 4 no indications for this 
were found.
The questionnaire is developed as an instrument to assess the impact of KC on patients’ 
lives and not so much to evaluate the effect of (different) treatments.
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A major limitation in the study described in chapter 3, the development and validation of 
the BaSQoL questionnaire, was that we did not compare the newly developed question-
naire to an existing one. In order to overcome this issue, we compared the BaSQoL to the 
Skin Cancer Index in the additional validation study of the English version of the BaSQoL 
in chapter 4.
Future perspective
The BaSQoL may be used in two different contexts. First it may be used on a group level, in 
a population based setting or a larger group of patients, for example in a hospital of clinic, 
to evaluate the impact of disease and care in general. It helps to assess which problems 
arise in KC patients, to help the physician address these items in outpatient consultations 
or to provide care and more extensive explanation by dermatology nurses. Furthermore, 
it can be used to measure before and after changes in care plans to assess the impact on 
group level (e.g. before and after reducing follow-up regimens for low risk KC patients or 
before and after implementation of new treatments). Variation between hospitals can also 
be assessed to identify and evaluate differences in order to improve care and learn from 
each other.
Second, the BaSQoL may be used on an individual patient level to assess the impact of 
the disease, diagnosis and the treatment. Although it was not developed for this purpose, 
it makes sense to use it as such. This has happened in the past with the EORTC QLQ-C30 
questionnaire and which has been commented on frequently. Determination of minimal 
clinically important differences or cut-off scores would help to guide the clinician in which 
patient is at risk for high impact and therefore requires additional attention and care. 
Also the way the scores are presented back to the patient or the physician may lead to 
easier interpretation; further research is necessary to optimize this aspect. Using the 
BaSQoL as an instrument to assess the level of distress in patients, identifying distressed 
patients and providing supportive care may also help to reduce healthcare costs overall, as 
it has been shown that distressed patients use more healthcare services in comparison to 
non-distressed patients or a normative population. [45] Additional studies are needed to 
identify patients who may need psychological care and to assess if psychosocial interven-
tions could reduce the frequency of medical contacts.
The data generated with studies from the first group (group-level data) can help to moni-
tor the patient’s PROs (individual-level data) and to compare individual-level data with 
mean group level outcomes. Knowledge about the patients individual PRO may even help 
in decision making in choosing the best suitable treatment. For example, a patient with a 
superficial BCC with high impact on the worries subscale might be better off treated with 
surgical excision with histopathological examination of the specimen instead of topical 
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treatment with 5-fluorouracil cream or imiquimod cream without the histopathological 
confirmation of the excision.
One of the greatest challenges is how to integrate routinely measurement of HRQoL instru-
ments such as the BaSQoL in daily practice. The BaSQoL is short and therefore quick and 
easy to complete for patients, but calculation and interpretation of the scores is still time 
consuming. Creation of a web-based form can help to display the scores immediate. How 
this data is displayed to optimize interpretability is also an important aspect to consider. 
Mean scores for example can be presented next to the individual score. It can be displayed 
as a number, but also in a graph such as a bar chart, pie chart or a line chart. Deviant scores 
can be displayed in a different color to simplify interpretation. One study demonstrated 
that the best way to display individual PRO scores is to use a line chart with high scores 
meaning better HRQoL and a threshold line within the chart to identify the scores below 
which are possibly concerning. [46]
It also has to be assessed what the optimal moment in time is for questionnaire admin-
istration (e.g. 1 month after treatment, 3 months after treatment). The clinical meaning 
or interpretation of the subscale scores is another area of attention for future research. 
It can be assessed on an individual patient level using anchor-based methodology, which 
examines the relationship between scores on an HRQoL instrument and an independent 
measure (anchor), or on a population level by statistical analysis appointing a score of 1 or 
2 SD above the mean as deviant. [47]
The use of modern technology such as questionnaire administration through apps and 
automated feedback to the patient and his/her electronic medical file about the PRO out-
comes with practical advice when to act, what to do and whom to discuss the results with 
may help to empower patients and to use the questionnaire in daily practice. This is also 
stated in the directives agreement (‘hoofdlijnen akkoord’) on speciality care 2019-2022 as 
stated by the current Dutch government. [48]
Conclusion
The perception of KC patients on their disease and treatment and the related HRQoL 
impact is captured in the newly developed BaSQoL questionnaire. This thesis presents 
studies on the development and validation of this questionnaire and factors influencing 
the HRQoL in KC patients. More research is needed to optimize the use and interpretation 
of the BaSQoL questionnaire in order to confirm and sustain the KC patient empowerment.
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Chapter 1 is the general introduction to this thesis. Keratinocyte carcinoma (KC) is a 
common health problem affecting a great number of patients. The different studies on 
health-related quality of life (HRQoL) instruments in KC published previous to this thesis 
are described. The first studies used generic and cancer specific HRQoL questionnaires. In 
these studies the relevance of many items was questioned by study participants. It may 
be concluded that affected domains of HRQoL in KC patients are not captured by generic 
and cancer specific questionnaires. Dermatology specific HRQoL questionnaires created 
for use in skin disease patients, in particular inflammatory skin disease. Measurement 
with these questionnaires in KC patients display some differences when comparing dif-
ferent treatment modalities, but still lack face validity and fail to capture the KC patients 
concerns in detail. The previous developed skin cancer specific HRQoL questionnaires do 
assess some important and relevant issues, but fail to capture the important behavioral 
changes of KC patients, interpretability is questionable due to multiple items in 1 question 
and face and content validity are lacking. Therefore the aims of this thesis were to develop 
and validate a disease-specific HRQoL questionnaire and assess HRQoL and patient per-
ception of disease, treatment and provided information in KC patients.
In chapter 2 we used the dermatology specific Skindex-17 questionnaire and the skin 
cancer specific Skin Cancer Index (SCI) in an open-label, multicenter study (2 university 
medical centers and 6 hospitals) in which patients with actinic keratosis (AK) and superfi-
cial basal cell carcinoma (sBCC) eligible for treatment with imiquimod 5% cream were in-
cluded. Treatment satisfaction was measured by the Treatment Satisfaction Questionnaire 
for Medication (TSQM). 118 AK and 84 sBCC patients were included and asked to complete 
the HRQoL questionnaires at baseline (before treatment), directly after treatment and 
8-16 weeks after treatment. TSQM was measured at the final measure point. Low baseline 
HRQoL impairment was found on the Skindex-17 and the SCI, which remained low after 
treatment, except for a small dip at the end of the application period. Imiquimod 5% cream 
treatment has no clinically relevant HRQoL improvement nor impairment in both AK and 
sBCC as measured by the Skindex-17 and the SCI. Treatment is well tolerated, but overall 
treatment satisfaction (as measured by the TSQM) is only around 55-60% in both groups. 
We concluded that the results of this study also suggest that the used HRQoL instruments 
are not specific and sensitive enough to capture the issues important in KC patients.
Chapter 3 describes the development and validation of the Basal and Squamous cell 
carcinoma Quality of Life (BaSQoL) questionnaire. This was primarily done in a 4 phase 
development, mostly following guidelines of the European Organisation for Research and 
Treatment of Cancer Quality of Life (EORTC QOL) group (phase 1: generating issues; phase 
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2: reduction of items; phase 3: pre-testing; phase 4: field testing). The first phase consisted 
of generating an extensive list of HRQoL issues relevant to KC patients. A focus group meet-
ing, semi-structured interviews with healthcare professionals and a literature search led 
to 57 issues which were presented to patients and healthcare professionals for relevance 
and priority rating. This led to a reduced 33 issues which were converted into items which 
were pre-tested in a 16 patients (phase 2 and 3). The provisional 33 item questionnaire 
was field-tested in 1,173 patients selected from the Netherlands Cancer Registry (phase 
4). 721 patients responded (61%) of which 85% had basal cell carcinoma (BCC) and 
15% squamous cell carcinoma (SCC). Principal component analyses were performed to 
determine the 5 components, which were labelled as Worries, Appearance, Behaviour, 
Diagnosis & Treatment and Other people. Item response analyses were used to reduce the 
number of items to 16. The performance of the new questionnaire was assessed by eight 
classical test theory features and with a confirmatory factor analysis, showing a good face, 
content and construct validity.
Chapter 4 describes the additional validation of the English translation of the BaSQoL. In 
this prospective, observational study, 122 BCC and 65 SCC patients were enrolled who were 
scheduled for treatment in the University of California, San Francisco. They were asked to 
fill in the BaSQoL questionnaire before treatment (T0), four weeks after treatment (T1) 
and one week thereafter (5 weeks after treatment; T2). Additionally, participants were 
asked to complete the SCI and the Hospital Anxiety and Depression Scale (HADS) one week 
before treatment. Mean scores for BaSQoL subscales were generally low, demonstrating a 
moderate impact on HRQoL for most patients. Patients with SCC had higher levels of anxi-
ety as measured by the Worries subscale in comparison to BCC patients. The SCI measured 
higher impact in SCC patients in the Emotional subscale. HADS scores were low, except for 
a few patients who indicated anxiety. The eight classical test theory features showed good 
performance. Internal consistency was good with Cronbach’s αs ranging from 0.63-0.80 
for the different subscales. The intra-class correlation coefficient (ICC) between T1 and T2 
was high (≥0.75) for nearly all subscales, indicating a stable response of the BaSQoL over 
time. BaSQoL subscales were strongly correlated with subscales of the SCI, demonstrating 
convergent validity, but were weakly correlated with HADS, indicating divergent validity. 
The English language version of the BaSQoL therefore has good face, content, and con-
struct validity. This study validates the English translation of the BaSQoL for use in a wide 
range of BCC and SCC patients.
In chapter 5 the BaSQoL questionnaire is used to measure HRQoL impact in BCC and SCC 
patients in a large population based sample from the Netherlands Cancer Registry. Ad-
ditional questionnaires regarding cancer-specific HRQoL (EORTC QLQ-C30), information 
provision (EORTC QLQ-INFO25) and general satisfaction with care (EORTC IN-PATSAT32) 
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were administered. 721 of 1,173 (61%) patients participated. HRQoL impact as measured 
by the BaSQoL was higher among female and younger patients. One third (N=237) of all 
patients indicated to be dissatisfied with the information provision as measured by the 
dichotomized item ‘satisfaction with information provision’ within the EORTC QLQ-INFO25 
questionnaire. Of all patients, 16% (N=116) indicated that they had wanted to receive more 
information about skin cancer in general, but also about causes, treatment and follow-up 
plan and how to recognize new lesions. This corresponds to 37% (84/225) of all dissatisfied 
patients and 7% (28/416) of the satisfied patients. Dissatisfaction with information provi-
sion was associated with younger age, facial tumour, not having a partner and multiple 
comorbidities. HRQoL was worse in patients dissatisfied with information provision (e.g. 
BaSQoL-worries mean score satisfied patients: 0.54 (95%CI:0.48–0.59 ), dissatisfied pa-
tients: 0.77 (95%CI:0.67–0.87 ), p=0.001). The distribution of satisfied versus dissatisfied 
with the information provision differed substantially between the 9 participating hospitals 
or clinics. However, after adjustment for patient and tumour characteristics, participating 
centre was no longer associated with satisfaction with information provision. Dissatisfac-
tion with provided information was associated with an impact on HRQoL. Possibly, HRQoL 
could be improved by improving the information provision.
In chapter 6 the BaSQoL questionnaire is used to measure impact of diagnosis and treat-
ment of KC in the head and neck area in a random population based sample of 347 patients, 
independent to the sample of the validation study. Additional questionnaires concerning 
cancer-specific HRQoL (EORTC QLQ-C30) and patient satisfaction with care (EORTC IN-
PATSAT32) were administered. One single item was used to assess the cosmetic results of 
the treatment. HRQoL was also compared to an age- and sex-matched norm population. 
215 patients (62%) participated. Patients with KC reported better global quality of life and 
less pain in comparison to the norm population. No statistically significant differences in 
HRQoL, satisfaction with care, and cosmetic results were found between patients with KC 
who underwent conventional excision, Mohs’ micrographic surgery, or radiotherapy. The 
impact of KC and its treatment is low and more positive than negative as patients reported 
better quality of life compared to a normative population. This information could be used 
by specialists involved in KC care to improve patients’ knowledge about different aspects 
of disease as patient’s preference is an important factor for treatment choice.

133
Samenvatting
SAmeNVAttING
Hoofdstuk 1 is de algemene introductie van dit proefschrift. Keratinocyt kanker (KC) is 
een veelvoorkomend gezondheidsprobleem wat bij veel patiënten voorkomt. De verschil-
lende studies op het gebied van gezondheid gerelateerde kwaliteit van leven (HRQoL) 
instrumenten bij patiënten met KC worden beschreven. De eerste studies gebruikten 
generieke en kanker specifieke HRQoL vragenlijsten. In deze studies gaven veel deelne-
mers aan de gestelde vragen niet zo relevant te vinden. Er mag geconcludeerd worden dat 
de aangedane domeinen van HRQoL bij KC patiënten niet voldoende gemeten worden in 
generieke en kanker specifieke vragenlijsten. Dermatologie specifieke HRQoL vragenlijsten 
zijn ontwikkeld om te gebruiken in patiënten met huidziekten, voornamelijk inflammatoire 
huidziekten. Metingen met deze vragenlijsten bij KC patiënten geven enkele verschillen 
weer wanneer verschillende behandelingen vergeleken worden, maar hebben onvoldo-
ende indruksvaliditeit en vangen de zorgen van KC patiënten onvoldoende nauwkeurig. 
De eerder ontwikkelde huidkanker specifieke HRQoL vragenlijsten meten wel enkele 
belangrijke en relevante zorgen, maar niet de belangrijke gedragsveranderingen bij KC 
patiënten. De interpretatie is twijfelachtig doordat één vraag verschillende items bevat 
en de indruks- en inhoudsvaliditeit zijn onvoldoende. Daarom was de doelstelling van dit 
proefschrift om een  ziektespecifieke HRQoL vragenlijst te ontwikkelen en te valideren en 
om de HRQoL en de perceptie van patiënten over ziekte, behandeling en informatie bij KC 
patiënten te beoordelen.
In hoofdstuk 2 hebben we de dermatologie specifieke Skindex-17 vragenlijst en de huid-
kanker specifieke Skin Cancer Index (SCI) gebruikt in een open-label multicenter studie 
(2 universitaire medische centra en 6 perifere ziekenhuizen). Hierbij zijn patiënten met 
actinische keratosen (AK) en superficiële basaalcelcarcinomen (sBCC) geïncludeerd  als ze 
geschikt waren voor behandeling met imiquimod 5% crème. De behandeltevredenheid 
werd gemeten met de Treatment Satisfaction Questionnaire for Medication (TSQM). 118 
AK en 84 sBCC patiënten werden geïncludeerd en gevraagd om de HRQoL vragenlijsten in 
te vullen bij aanvang van de studie (voorafgaand aan behandeling), direct na de behandel-
ing en 8-16 weken na de behandeling. De TSQM is alleen afgenomen op het laatste meet-
punt. Lage HRQoL uitgangsscores werden gevonden op de Skindex-17 en de SCI, welke 
laag bleven na behandeling, wat een lage impact op de HRQoL aangeeft, met uitzondering 
van een korte verslechtering aan het einde van de applicatieperiode. Imiquimod 5% crème 
gaf geen klinisch relevante HRQoL verbetering of verslechtering bij zowel AK en sBCC zoals 
gemeten met de Skindex-17 en SCI. De behandeling werd goed verdragen, maar globale 
behandeltevredenheid (zoals gemeten met de TSQM) is slechts rond de 55-60% in beide 
groepen. Wij concludeerden dat de resultaten van deze studie ook suggereren dat de 
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gebruikte HRQoL instrumenten niet specifiek en sensitief genoeg zijn om de belangrijkste 
zorgen die van belang zijn in KC patiënten te ondervangen.
Hoofdstuk 3 beschrijft de ontwikkeling en validatie van de Basal and Squamous cell 
carcinoma Quality of Life (BaSQoL) vragenlijst. De ontwikkeling van de vragenlijst vond 
in eerste instantie plaats in 4 fasen, waarbij we de richtlijnen van de European Organisa-
tion for Research and Treatment of Cancer Quality of Life (EORTC QOL) groep zo goed 
als mogelijk gevolgd hebben (fase 1: genereren van HRQoL punten; fase 2: reductie van 
items; fase 3: pre-testen; fase 4: veldtesten). De eerste fase bestond uit het genereren 
van een uitgebreide lijst met HRQoL punten welke relevant zijn voor KC patiënten. Een fo-
cusgroep bijeenkomst, semigestructureerde interviews met zorgverleners en een literatu-
uronderzoek leidde tot een lijst van 57 punten welke voorgelegd werden aan patiënten en 
zorgverleners ter beoordeling van de relevantie en ter prioritering. Hierdoor werd de lijst 
gereduceerd tot 33 punten welke omgezet werden naar items. Deze werden voorafgaand 
aan het verdere onderzoek getest door 16 patiënten (fase 2 en 3). De voorlopige vragenli-
jst met 33 items werd in de praktijk getest in 1,173 patiënten welke geselecteerd werden 
uit de Nederlandse Kankerregistratie (fase 4). 721 patiënten reageerden (61%) waarvan 
85% basaalcelcarcinoom (BCC) had en 15% plaveiselcelcarcinoom (PCC). Principale com-
ponenten analyse werd uitgevoerd om uiteindelijk 5 componenten vast te stellen, welke 
zijn bestempeld als Zorgen, Uiterlijk, Gedrag, Diagnose & Behandeling en Andere mensen. 
Item response analyses werden gebruikt om het aantal items terug te brengen naar 16. 
Het presteren van de nieuwe vragenlijst werd beoordeeld met acht criteria volgens de 
klassieke test theorie en met een bevestigende factoranalyse en toonde een goede in-
druks- en inhouds- en begripsvaliditeit.
Hoofdstuk 4 beschrijft de aanvullende validatie van de Engelse vertaling van de BaSQoL. 
In deze prospectieve, observationele studie werden 122 BCC en 65 PCC patiënten geïnclu-
deerd welke gepland stonden voor behandeling in het ziekenhuis van de universiteit van 
California, San Francisco. Aan hen werd gevraagd om de BaSQoL vragenlijst in te vullen 
voorafgaand aan behandeling (T0), vier weken na behandeling (T1) en één week daarna 
(5 weken na behandeling; T2). Aanvullend werd aan de deelnemers gevraagd om de 
SCI en de Hospital Anxiety and Depression Scale (HADS) in te vullen één week voor de 
behandeling. In het algemeen waren de gemiddelde BaSQoL subschaal scores laag, wat 
een matige impact op de HRQoL aangeeft voor de meeste patiënten. Patiënten met PCC 
rapporteerden meer angst (gemeten met de Zorgen subschaal) in vergelijking met de BCC 
patiënten. De SCI toonde een hogere impact bij PCC patiënten in de Emoties subschaal. 
HADS scores waren laag, met uitzondering van enkele patiënten welke angst aangaven. De 
acht criteria volgens de klassieke test theorie toonden dat de lijst goed presteert. Interne 
validiteit was goed met Cronbach’s α’s tussen 0.63-0.80 voor de verschillende subschalen. 
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De intraklasse correlatie coëfficiënt (ICC) tussen T1 en T2 was hoog (≥0.75) voor vrijwel 
alle subschalen, wat een stabiele weergave van de BaSQoL over de tijd weergeeft. De 
BaSQoL subschalen hadden een hoge correlatie met de subschalen van de SCI, wat een 
goede convergente validiteit betekent. De correlatie met de HADS was laag, wat een go-
ede divergente validiteit betekent. De Engelse versie van de BaSQoL heeft dus een goede 
indruks-, inhouds- en begripsvaliditeit. Deze studie valideert de Engelse vertaling van de 
BaSQoL voor gebruik in het gehele spectrum van BCC en PCC patiënten.
In hoofdstuk 5 is de BaSQoL gebruikt om HRQoL impact te meten bij BCC en PCC patiënten 
in een grote steekproef van de bevolking vanuit de Nederlandse Kankerregistratie. Aanvul-
lende vragenlijsten over kanker-specifieke HRQoL (EORTC QLQ-C30), informatievoorzien-
ing (EORTC QLQ-INFO25) en algemene tevredenheid met zorg (EORTC IN-PATSAT32) zijn 
afgenomen. 721 van de 1.173 (61%) patiënten namen deel aan de studie. HRQoL impact 
zoals gemeten met de BaSQoL was hoger bij vrouwelijke en jongere patiënten. Eén derde 
(N=237) van alle patiënten gaf aan ontevreden te zijn over de gegeven informatie zoals 
gemeten met het gedichotomiseerde item ‘tevredenheid met informatievoorziening’ 
binnen de EORTC QLQ-INFO25 vragenlijst. Van alle patiënten gaf 16% (N=116) aan dat ze 
meer informatie hadden willen ontvangen over huidkanker in het algemeen, maar ook 
over oorzaken, behandelingen en follow-up en hoe nieuwe plekken te herkennen. Dit ver-
houd zich tot 37% (84/225) van alle ontevreden patiënten en 7% (28/416) van de tevreden 
patiënten. Ontevredenheid met de ontvangen informatie was geassocieerd met jongere 
leeftijd, tumorlokalisatie in het gezicht, geen partner hebben en het hebben van meerdere 
comorbiditeiten. HRQoL was slechter bij patiënten die ontevreden waren over de ontvan-
gen informatie (bijvoorbeeld: de BaSQoL Zorgen gemiddelde score bij tevreden patiënten: 
0.54 (95% CI: 0.48-0.59), ontevreden patiënten: 0.77 (95% CI: 0.67-0.87), p= 0.001). De 
verdeling van tevreden versus ontevreden patiënten over de ontvangen informatie ver-
schilde wezenlijk tussen de 9 deelnemende ziekenhuizen en zelfstandige behandelcentra. 
Echter, na correctie voor patiënt en tumorkarakteristieken was de variabele ‘deelnemend 
centrum’ niet langer geassocieerd met tevredenheid over de ontvangen informatie. Onte-
vredenheid over de ontvangen informatie was geassocieerd met een impact op de HRQoL. 
Mogelijk kan de HRQoL verbeterd worden door de informatievoorziening te verbeteren.
In hoofdstuk 6 is de BaSQoL vragenlijst gebruikt om de impact te meten van diagnose 
en behandeling van KC in het hoofdhals gebied in een willekeurige steekproef van 347 
patiënten, onafhankelijk van de steekproef van de validatie studie. Aanvullende vragen-
lijsten over kanker-specifieke HRQoL (EORTC QLQ-C30) en algemene tevredenheid met 
zorg (EORTC IN-PATSAT32) zijn afgenomen. Eén item is gebruikt om het cosmetische 
resultaat van de behandeling vast te stellen. HRQoL is ook vergeleken met een aan leeftijd 
en geslacht gekoppelde norm populatie. 215 patiënten (62%) namen deel aan de studie. 
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Patiënten met KC rapporteerden een betere algehele kwaliteit van leven en minder pijn in 
vergelijking met de normpopulatie. Geen statistisch significante verschillen werden gevon-
den met betrekking tot HRQoL, tevredenheid met zorg en cosmetisch resultaat  tussen KC 
patiënten die behandeld werden met conventionele excisie, Mohs’ micrografische chirur-
gie en radiotherapie. De impact van KC en de behandeling bleek laag en meer positief 
dan negatief, aangezien de KC patiënten een betere kwaliteit van leven rapporteerden in 
vergelijking met de norm populatie. Deze informatie kan gebruikt worden door speciali-
sten die betrokken zijn bij KC behandeling om de kennis van patiënten over verschillende 
aspecten van ziekte te verbeteren, aangezien patiëntenvoorkeur een belangrijke factor 
speelt bij keuze voor een behandeling.
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BaSQoL-NL
BaSQoL-NL
De volgende vragen gaan over de invloed van de huidkanker op uw dagelijks leven
Sinds de diagnose huidkanker, Helemaal 
niet
een 
beetje
Nogal Heel 
erg
1. Vindt u het vervelend dat u moet letten op uw zongedrag? ⎕ ⎕ ⎕ ⎕
2.  Vindt u het vervelend dat u meer zonnebrandproduct (crème, spray, 
etc.) moet gebruiken? ⎕ ⎕ ⎕ ⎕
3.  Vindt u het vervelend dat u uw huid moet controleren op 
huidkanker? ⎕ ⎕ ⎕ ⎕
4.  Vindt u het vervelend uw huid beter te moeten beschermen tegen 
de zon? ⎕ ⎕ ⎕ ⎕
5.  Heeft u het gevoel anderen te moeten aanmoedigen om hun huid 
te laten controleren? ⎕ ⎕ ⎕ ⎕
Als u terugdenkt aan de periode van diagnose en behandeling, Helemaal 
niet
een 
beetje
Nogal Heel
erg
6.  Maakte u zich zorgen over de periode tussen diagnose en 
behandeling? ⎕ ⎕ ⎕ ⎕
7. Was u bang voor de behandeling? ⎕ ⎕ ⎕ ⎕
8. Was u geschrokken van het woord kanker? ⎕ ⎕ ⎕ ⎕
Gedurende de afgelopen week, Helemaal 
niet
een 
beetje
Nogal Heel
erg
9. Was u bang om op meerdere plaatsen huidkanker te krijgen? ⎕ ⎕ ⎕ ⎕
10. Maakte u zich zorgen over uitzaaiingen? ⎕ ⎕ ⎕ ⎕
11. Was u onzeker over de toekomst? ⎕ ⎕ ⎕ ⎕
12. Maakte u zich zorgen over andere huidafwijkingen? ⎕ ⎕ ⎕ ⎕
13. Maakte u zich zorgen verminderd aantrekkelijk te zijn? ⎕ ⎕ ⎕ ⎕
14.  Vond u het vervelend om uw kleding aan te passen om littekens en 
plekken te bedekken? ⎕ ⎕ ⎕ ⎕
15. Voelde u zich minder aantrekkelijk? ⎕ ⎕ ⎕ ⎕
16. Maakte u zich zorgen over de huid van anderen? ⎕ ⎕ ⎕ ⎕
BaSQoL-EN
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BaSQoL-eN
the following questions are about the influence of skin cancer on your daily life
Since the skin cancer diagnosis, Not 
at all
A 
little
Quite
 a bit
Very 
much
17. Does it bother you to be careful about your behavior in 
the sun? ⎕ ⎕ ⎕ ⎕
18. Does it bother you to use more suncreen (cream, spray, 
etc.)? ⎕ ⎕ ⎕ ⎕
19. Does it bother you to check your skin for skin cancer? ⎕ ⎕ ⎕ ⎕
20. Does it bother you to have to protect your skin from the 
sun? ⎕ ⎕ ⎕ ⎕
21. Do you feel that you have to encourage others to get 
their skin checked? ⎕ ⎕ ⎕ ⎕
When you think back to the time of diagnosis and 
treatment,
Not 
at all
A 
little
Quite 
a bit
Very 
much
22. Were you worried about the period between diagnosis 
and treatment? ⎕ ⎕ ⎕ ⎕
23. Were you afraid of the treatment? ⎕ ⎕ ⎕ ⎕
24. Were you frightened by the word cancer? ⎕ ⎕ ⎕ ⎕
During the past week, Not 
at all
A 
little
Quite 
a bit
Very 
much
25. Were you afraid to get skin cancer on multiple body 
sites? ⎕ ⎕ ⎕ ⎕
26. Were you worried about skin cancer spreading to other 
parts of the body? ⎕ ⎕ ⎕ ⎕
27. Were you uncertain about the future? ⎕ ⎕ ⎕ ⎕
28. Were you worried about other skin disorders? ⎕ ⎕ ⎕ ⎕
29. Were you worried that you would be less attractive? ⎕ ⎕ ⎕ ⎕
30. Did it bother you to adjust your clothing in order to cover 
your scars and spots? ⎕ ⎕ ⎕ ⎕
31. Did you feel less attractive? ⎕ ⎕ ⎕ ⎕
32. Were you worried about other people’s skin? ⎕ ⎕ ⎕ ⎕
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ABBReVAtIONS
2PL-ltm  2-Parameter latent trait model
5-FU  5-fluorouracil
AK  Actinic Keratosis
AKQoL  Actinic Keratosis Quality of Life
ANS  Actinic Neoplasia Syndrome
BaSQoL  Basal and Squamous cell carcinoma Quality of Life
BCC  Basal Cell Carcinoma
CFI  Comparative Fit Index
CoRPS  Centre of Research on Psychology in Somatic diseases
CTT  Classical Test Theory
DCE  Discrete Choice Experiment
DLQI  Dermatology Life Quality Index
ENT  Ear Nose and Throat
EORTC  European Organization for Research and Treatment of Cancer
FACT-G  Functional Assessment of Cancer Therapy-General
FDR  False Discovery Rate
HADS  Hospital Anxiety and Depression Scale
HCP  Healthcare Provider
HRQoL  Health-Related Quality of Life
ICC  Intra-class Correlation Coefficient
ICD-O3  International Classification of Disease for Oncology
IKNL  Netherlands Comprehensive Cancer Organization
INPATSAT-32 Satisfaction with in-patient cancer care-32
IQR  Interquartile Range
IRT  Item Response Theory
KC  Keratinocyte Carcinoma
MLMV  Maximum Likelihood with Missing Values
MM  Malignant Melanoma
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The cover photograph is part of the artwork Second-
wind by James Turrell and was taken in 2018 at the 
NMAC Foundation in Vejer de la Frontera, Spain. It 
is one of many Skyspaces; specifically proportioned 
chambers with an aperture in the ceiling open to the 
sky. The construction guides the viewer’s experience 
and transforms light into an object of art.
By focusing the attention we are able to observe more 
features and details, similar as in dermatology and dis-
ease specific quality of life.
This thesis describes several studies on aspects of 
health-related quality of life and the development and 
validation of a disease specific quality of life question-
naire for keratinocyte cancer patients.
